Download Publications

Edith A. Perez
Edith A. Perez, M.D., is Deputy Director, Mayo Clinic Cancer Center, Mayo Clinic in
Florida. She also serves as Director of the Breast Program, and is a Serene M. and
Frances C. Durling Professor of Medicine, Mayo Medical School.
Dr. Perez is a cancer specialist and an internationally known translational researcher
at Mayo Clinic. Her roles extend nationally, including chairing the Breast Committee
for the North Central Cancer Treatment Group, as well as other positions within the
American Association for Cancer Research; the American Society of Clinical
Oncology and the National Cancer Institute.
She has developed, and is involved in, a wide range of clinical trials exploring the use
of new therapeutic agents for the treatment and prevention of breast cancer. Dr. Perez
also has developed studies to evaluate the role of genetic markers in the development
and aggressiveness of breast cancer.
She has authored more than 550 research articles in journals, books and abstracts. Dr.
Perez is invited frequently to lecture at national and international meetings; and serves
on the editorial boards of multiple academic journals.
Dr. Perez is a recipient of the following awards:
 Breast
Cancer Research Foundation Research Grant Award (1998-2011)
 Horizon
Achievement Award in Cancer Research (2002)
 North
Florida Hispanic of the Year Award (2003)
 Mayo
Clinic Outstanding Faculty Award (2002 & 2004)
 Mayo
Clinic Distinguished Educator Award (2003)
 Serene M.
and Frances C. Durling Professorship of Medicine (2006)
 Honorary Doctorate of
 Mayo
Letters, University of North Florida (2006)
Clinic Distinguished Investigator (2007)
 Florida State
Biomedical Research Advisory Council (BRAC) (2009-2012)
 Membership
to Alpha Omega Alpha Honor Medical Society (2009
 Mayo
 EVE
Clinic Outstanding Course Director (2009)
Award for Lifetime Achievement (2011)
Education
 Fellowship
– Hematology and Oncology
Martinez VA Medical Center, School of Medicine, University of California, Davis
 Residency
– Internal Medicine
Loma Linda University Medical Center
 M.D.
University of Puerto Rico School of Medicine
 B.S.
– Biology
University of Puerto Rico, Rio Piedras
Publications
1. Perez EA, Romond EH, Suman VJ, Jeong JH, Davidson NE, Geyer CE Jr,
Martino S, Mamounas EP, Kaufman PA, Wolmark N. Four-Year Follow-Up of
Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth
Factor Receptor 2-Positive Breast Cancer: Joint Analysis of Data From NCCTG
N9831 and NSABP B-31. J Clin Oncol. 2011 Jul 18. [Epub ahead of print]
2. Adkisson CD, Vallow LA, Kowalchik K, McNeil R, Hines S, Deperi E, Moreno
A, Roy V, Perez EA, McLaughlin SA. Patient age and preoperative breast MRI in
women with breast cancer: biopsy and surgical implications. Ann Surg Oncol. 2011
Jun; 18(6):1678-83. Epub 2011 Jan 05.
3. Andorfer CA, Necela BM, Thompson EA, Perez EA. MicroRNA signatures:
clinical biomarkers for the diagnosis and treatment of breast cancer. Trends Mol
Med. 2011 Jun; 17(6):313-9. Epub 2011 Mar 02.
4. Asmann YW, Hossain A, Necela BM, Middha S, Kalari KR, Sun Z, Chai HS,
Williamson DW, Radisky D, Schroth GP, Kocher JP, Perez EA, Thompson EA. A
novel bioinformatics pipeline for identification and characterization of fusion
transcripts in breast cancer and normal cell lines. Nucleic Acids Res. 2011 May 27.
[Epub ahead of print]
5. Mathew J, Vishnu P, Perez EA. Highlights from the 3rd Breast-Gynecological
International Cancer Conference 2011. Expert Rev Anticancer Ther. 2011 May;
11(5):701-4.
6. Robert NJ, Dieras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, Perez
EA, Yardley DA, Chan SY, Zhou X, Phan SC, O'Shaughnessy J. RIBBON-1:
randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with
or without bevacizumab for first-line treatment of human epidermal growth factor
receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 2011
Apr 1; 29(10):1252-60. Epub 2011 Mar 07.
7. Ganz PA, Land SR, Geyer CE Jr, Cecchini RS, Costantino JP, Pajon ER,
Fehrenbacher L, Atkins JN, Polikoff JA, Vogel VG, Erban JK, Livingston
RB, Perez EA, Mamounas EP, Wolmark N, Swain SM. Menstrual history and
quality-of-life outcomes in women with node-positive breast cancer treated with
adjuvant therapy on the NSABP B-30 trial. J Clin Oncol. 2011 Mar 20; 29(9):11106. Epub 2011 Feb 07.
8. Ellis GK, Barlow WE, Gralow JR, Hortobagyi GN, Russell CA, Royce
ME, Perez EA, Lew D, Livingston RB. Phase III comparison of standard
doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral
cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant
therapy for inflammatory and locally advanced breast cancer: SWOG 0012. J Clin
Oncol. 2011 Mar 10; 29(8):1014-21. Epub 2011 Jan 10.
9. Perez EA, Jenkins RB, Dueck AC, Wiktor AE, Bedroske PP, Anderson SK,
Ketterling RP, Sukov WR, Kanehira K, Chen B, Geiger XJ, Andorfer CA,
McCullough AE, Davidson NE, Martino S, Sledge GW, Kaufman PA, Kutteh LA,
Gralow JR, Harris LN, Ingle JN, Lingle WL, C-MYC alterations and association
with patient outcome in early-stage HER2-positive breast cancer from the north
central cancer treatment group N9831 adjuvant trastuzumab trial. J Clin Oncol. 2011
Feb 20; 29(6):651-9. Epub 2011 Jan 18.
10.
Perez EA. Breast cancer management: opportunities and barriers to an
individualized approach. Oncologist. 2011; 16 Suppl 1:20-2.
11.
Sun Z, Asmann YW, Kalari KR, Bot B, Eckel-Passow JE, Baker TR, Carr
JM, Khrebtukova I, Luo S, Zhang L, Schroth GP, Perez EA, Thompson EA.
Integrated analysis of gene expression, CpG island methylation, and gene copy
number in breast cancer cells by deep sequencing. PLoS One. 2011; 6(2):e17490.
Epub 2011 Feb 25.
12.
Roche H, Conte P, Perez EA, Sparano JA, Xu B, Jassem J, Peck R, Kelleher
T, Hortobagyi GN. Ixabepilone plus capecitabine in metastatic breast cancer patients
with reduced performance status previously treated with anthracyclines and taxanes:
A pooled analysis by performance status of efficacy and safety data from 2 phase III
studies. Breast Cancer Res Treat. 2011; 125(3):755-65.
13.
Perez E. New biomarkers for intervention in breast cancer. Clin. adv.
hematol. oncol. 2011; 9(5):14.
14.
Swain SM, Jeong JH, Geyer CE, Costantino JP, Pajon ER, Fehrenbacher L,
Atkins JN, Polikoff J, Vogel VG, Erban JK, Rastogi P, Livingston RB, Perez EA,
Mamounas EP, Land SR, Ganz PA, Wolmark N. Longer therapy, iatrogenic
amenorrhea, and survival in early breast cancer. Obstet Gynecol Surv. 2010 Nov;
65(11):710-2.
15.
Perez EA, Reinholz MM, Hillman DW, Tenner KS, Schroeder MJ,
Davidson NE, Martino S, Sledge GW, Harris LN, Gralow JR, Dueck AC, Ketterling
RP, Ingle JN, Lingle WL, Kaufman PA, Visscher DW, Jenkins RB. HER2 and
chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. J
Clin Oncol. 2010 Oct 1; 28(28):4307-15. Epub 2010 Aug 09.
16.
Perez EA, Dirix L, Kocsis J, Gianni L, Lu J, Vinholes J, Ng V, Linehan C,
Agresta S, Hurvitz S. Efficacy and safety of trastuzumab-DM1 versus trastuzumab
plus docetaxel in HER2-positive metastatic breast cancer patients with no prior
chemotherapy for metastatic disease: preliminary results of a randomized,
multicenter, open-label phase 2 study (TDM4450G). Ann Oncol. 2010 Oct;
21(Suppl 8):2.
17.
Vahdat LT, Thomas E, Roche H, Hortobagyi GN, Sparano J, Yelle L,
Fornier MN, Martin M, Bunnell C, Perez E. Ixabepilone ( IXA)-associated
peripheral neuropathy (PN): retrospective review of data from phase II and III
clinical trials. Ann Oncol. 2010 Oct; 21(Suppl 8):109-10.
18.
Perez EA. Challenges in applying recent clinical trial data to the care of
patients. Clin Breast Cancer. 2010 Sep; 10 Suppl 2:S6.
19.
Pockaj BA, Wasif N, Dueck AC, Wigle DA, Boughey JC, Degnim AC, Gray
RJ, McLaughlin SA, Northfelt DW, Sticca RP, Jakub JW, Perez EA.
Metastasectomy and surgical resection of the primary tumor in patients with stage
IV breast cancer: time for a second look? Ann Surg Oncol. 2010 Sep; 17(9):241926. Epub 2010 Mar 16.
20.
Bryce AH, Mattar B, Hillman SL, Adjei AA, Kugler JW, Rowland K Jr,
Wender DB, Soori G, Perez EA, Jett JR. Phase II trial of oral topotecan and
intravenous carboplatin with G-CSF support in previously untreated patients with
extensive stage small cell lung cancer: A North Central Cancer Treatment Group
Study. Am J Clin Oncol. 2010 Aug; 33(4):353-7.
21.
Huang W, Reinholz M, Weidler J, Yolanda L, Paquet A, Whitcomb J, Lingle
W, Jenkins RB, Chen B, Larson JS, Tan Y, Sherwood T, Bates M, Perez EA.
Comparison of central HER2 testing with quantitative total HER2 expression and
HER2 homodimer measurements using a novel proximity-based assay. Am J Clin
Pathol. 2010 Aug; 134(2):303-11.
22.
Brufsky A, Vogel C, Seidler C, Bosserman L, Jin L, Warsi G, Aigonza-
Aviles E, Ericson S, Perez EA. A 5-year report on Bone-specific alkaline
phosphatase (BSAP) and serum N-telopeptide (sNTX) as predictors of bone loss in
postmenopausal women with early breast cancer receiving letrozole as adjuvant
therapy: Z-FAST. Bone. 2010 Jul; 47(Suppl 2):S309-10.
23.
Hillman SL, Mandrekar SJ, Bot B, DeMatteo RP, Perez EA, Ballman KV,
Nelson H, Buckner JC, Sargent DJ. Evaluation of the value of attribution in the
interpretation of adverse event data: a North Central Cancer Treatment Group and
American College of Surgeons Oncology Group investigation. J Clin Oncol. 2010
Jun 20; 28(18):3002-7. Epub 2010 May 17.
24.
Swain SM, Jeong JH, Geyer CE Jr, Costantino JP, Pajon ER, Fehrenbacher
L, Atkins JN, Polikoff J, Vogel VG, Erban JK, Rastogi P, Livingston RB, Perez EA,
Mamounas EP, Land SR, Ganz PA, Wolmark N. Longer therapy, iatrogenic
amenorrhea, and survival in early breast cancer. N Engl J Med. 2010 Jun 3;
362(22):2053-65.
25.
Perez EA, Patel T, Moreno-Aspitia A. Efficacy of ixabepilone in
ER/PR/HER2-negative (triple-negative) breast cancer. Breast Cancer Res Treat.
2010 Jun; 121(2):261-71. Epub 2010 Mar 13.
26.
Palmieri FM, Myatt CV, Perez EA. Adjuvant trastuzumab for HER2-
positive early breast cancer. Clin J Oncol Nurs. 2010 Jun; 14(3):326-36.
27.
Saurel CA, Patel TA, Perez EA. Changes to adjuvant systemic therapy in
breast cancer: a decade in review. Clin Breast Cancer. 2010 Jun; 10(3):196-208.
28.
Partridge AH, Archer L, Kornblith AB, Gralow J, Grenier D, Perez E, Wolff
AC, Wang X, Kastrissios H, Berry D, Hudis C, Winer E, Muss H. Adherence and
persistence with oral adjuvant chemotherapy in older women with early-stage breast
cancer in CALGB 49907: adherence companion study 60104. J Clin Oncol. 2010
May 10; 28(14):2418-22. Epub 2010 Apr 05.
29.
Ingle JN, Buzdar AU, Schaid DJ, Goetz MP, Batzler A, Robson ME,
Northfelt DW, Olson JE, Perez EA, Desta Z, Weintraub RA, Williard CV,
Flockhart DA, Weinshilboum RM. Variation in anastrozole metabolism and
pharmacodynamics in women with early breast cancer. Cancer Res. 2010 Apr 15;
70(8):3278-86. Epub 2010 Mar 30.
30.
Sparano JA, Pisano ED, White JR, Hunt KK, Mamounas EP, Perez EA,
Hortobagyi GN, Gralow JR, Comis RL. Recommendations for research priorities in
breast cancer by the coalition of cancer cooperative groups scientific leadership
council: imaging and local therapy. Breast Cancer Res Treat. 2010 Apr; 120(2):273-
84. Epub 2009 Dec 19.
31.
Perez EA, Moreno-Aspitia A, Aubrey Thompson E, Andorfer CA. Adjuvant
therapy of triple negative breast cancer. Breast Cancer Res Treat. 2010 Apr;
120(2):285-91. Epub 2010 Jan 22.
32.
Hines SL, Sloan JA, Atherton PJ, Perez EA, Dakhil SR, Johnson DB, Reddy
PS, Dalton RJ, Mattar BI, Loprinzi CL. Zoledronic acid for treatment of osteopenia
and osteoporosis in women with primary breast cancer undergoing adjuvant
aromatase inhibitor therapy. Breast. 2010 Apr; 19(2):92-6. Epub 2010 Jan 15.
33.
Bernard JR Jr, Vallow LA, DePeri ER, McNeil RB, Feigel DG, Amar S,
Buskirk SJ, Perez EA. In newly diagnosed breast cancer, screening MRI of the
contralateral breast detects mammographically occult cancer, even in elderly
women: the mayo clinic in Florida experience. Breast J. 2010 Mar-Apr; 16(2):11826. Epub 2010 Jan 29.
34.
Bondarenko I, Glaspy J, Brufsky A, Lipatov O, Perez EA, Chan S, Zou X,
Phan SC, Robert NJ, Dieras V. PFS by patient subgroup for standard
chemotherapies in combination with bevacizumab (BV) in the first-line treatment of
HER2-negative locally recurrent (LR) or metastatic breast cancer (mBC): results
from RIBBON-1. [Abstract #476]. EJC Supplements. 2010 Mar; 8(3):198.
35.
Tan WW, Hillman DW, Salim M, Northfelt DW, Anderson DM, Stella PJ,
Niedringhaus R, Bernath AM, Gamini SS, Palmieri F,Perez EA. N0332 phase 2 trial
of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast
cancer: a North Central Cancer Treatment Group (NCCTG) Trial. Ann Oncol. 2010
Mar; 21(3):493-7. Epub 2009 Jul 22.
36.
McCullough AE, Chen B, Hillman DW, Tenner KS, Jenkins RB, Reinholz
MM, Lingle WL, Dueck AC, Perez EA. 100% Concordance between IHC and FISH
HER2 testing cannot be achieved using N9831 cohort (Abstract 267). Mod Pathol.
2010 Feb; 23(Suppl 1):62A.
37.
McCullough AE, Chen B, Hillman DW, Tenner KS, Jenkins RB, Reinholz
MM, Lingle WL, Dueck AC, Perez EA. 100% concordance between IHC and FISH
HER2 testing cannot be achieved using N9831 cohort (Abstract 267). Lab Invest.
2010 Feb; 90(Suppl 1):62A.
38.
Sparano JA, Hortobagyi GN, Gralow JR, Perez EA, Comis RL.
Recommendations for research priorities in breast cancer by the Coalition of Cancer
Cooperative Groups Scientific Leadership Council: systemic therapy and therapeutic
individualization. Breast Cancer Res Treat. 2010 Feb; 119(3):511-27. Epub 2009
Jun 14.
39.
Moulder S, Li H, Wang M, Gradishar WJ, Perez EA, Sparano JA, Pins M,
Yang X, Sledge GW. A phase II trial of trastuzumab plus weekly ixabepilone and
carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern
Cooperative Oncology Group Trial. Breast Cancer Res Treat. 2010 Feb; 119(3):66371.
40.
Perez EA, Hillman DW, Dentchev T, Le-Lindqwister NA, Geeraerts LH,
Fitch TR, Liu H, Graham DL, Kahanic SP, Gross HM, Patel TA, Palmieri FM,
Dueck AC. North Central Cancer Treatment Group (NCCTG) N0432: phase II trial
of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for
patients with metastatic breast cancer. Ann Oncol. 2010 Feb; 21(2):269-74. Epub
2009 Nov 09.
41.
Burnell M, Levine MN, Chapman JA, Bramwell V, Gelmon K, Walley B,
Vandenberg T, Chalchal H, Albain KS, Perez EA, Rugo H, Pritchard K, O'Brien P,
Shepherd LE. Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense
epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and
cyclophosphamide followed by Paclitaxel in node-positive or high-risk nodenegative breast cancer. J Clin Oncol. 2010 Jan 1; 28(1):77-82. Epub 2009 Nov 09.
42.
Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT,
Ravdin P, Bugarini R, Baehner FL, Davidson NE, Sledge GW, Winer EP, Hudis C,
Ingle JN, Perez EA, Pritchard KI, Shepherd L, Gralow JR, Yoshizawa C, Allred
DC, Osborne CK, Hayes DF, Breast Prognostic and predictive value of the 21-gene
recurrence score assay in postmenopausal women with node-positive, oestrogenreceptor-positive breast cancer on chemotherapy: a retrospective analysis of a
randomised trial. Lancet Oncol. 2010 Jan; 11(1):55-65. Epub 2009 Dec 10.
43.
Slovak ML, Bedell V, Lew D, Albain KS, Ellis GK, Livingston RB, Martino
S, Perez EA, Hortobagyi GN, Sher D, Stock W. Screening for clonal hematopoiesis
as a predictive marker for development of therapy-related myeloid neoplasia (t-MN)
following neoadjuvant therapy for breast cancer: a Southwest Oncology Group study
(S0012). Breast Cancer Res Treat. 2010 Jan; 119(2):391-8.
44.
Shah SS, Ketterling RP, Goetz MP, Ingle JN, Reynolds CA, Perez EA, Chen
B. Impact of American Society of Clinical Oncology/College of American
Pathologists guideline recommendations on HER2 interpretation in breast cancer.
Hum Pathol. 2010 Jan; 41(1):103-6. Epub 2009 Sep 16.
45.
Patel TA, Perez EA. Metastatic breast cancer. In: Jatoi I; Kaufmann M
editor. Management of breast diseases. Heidelberg; New York: Springer; 2010. p.
425-49.
46.
Moreno Aspitia A, Perez EA. Side effects of systemic therapy:
neurocognitive, cardiac, and secondary malignancies. In: Harris JR; et al, editor.
Diseases of the breast. 4th Edition. Philadelphia: Wolters Kluwer Health/Lippincott
Williams & Wilkins; 2010. p. 692-704.
47.
Amar S, McCullough AE, Tan W, Geiger XJ, Boughey JC, McNeil RB,
Coppola KE, McLaughlin SA, Palmieri FM, Perez EA. Prognosis and outcome of
small (<=1 cm), node-negative breast cancer on the basis of hormonal and HER-2
status. Oncologist. 2010; 15(10):1043-9. Epub 2010 Oct 07.
48.
Santana-Davila R, Perez EA. Treatment options for patients with triple-
negative breast cancer. J Hematol Oncol. 2010; 3:42. Epub 2010 Oct 27.
49.
Reinholz MM, Eckel-Passow JE, Anderson SK, Asmann YW, Zschunke
MA, Oberg AL, McCullough AE, Dueck AC, Chen B, April CS, Wickham-Garcia
E, Jenkins RB, Cunningham JM, Jen J, Perez EA, Fan JB, Lingle WL. Expression
profiling of formalin-fixed paraffin-embedded primary breast tumors using cancerspecific and whole genome gene panels on the DASL(R) platform. BMC Med
Genomics. 2010; 3:60. Epub 2010 Dec 20.
50.
Patel TA, Colon-Otero G, Bueno Hume C, Copland JA 3rd, Perez EA.
Breast cancer in Latinas: gene expression, differential response to treatments, and
differential toxicities in Latinas compared with other population groups. Oncologist.
2010; 15(5):466-75. Epub 2010 Apr 28.
51.
Patel TA, Moreno-Aspitia A, Hume CB, Saurel C, Roy V, Perez EA. A
retrospective review of patients with adenoid cystic breast cancer treated at Mayo
Clinic. Cancer Res. 2009 Dec 15; 69(Suppl 3):610S.
52.
Brufsky A, Harker G, Beck JT, Carroll R, Jin L, Warsi G, Argonza-Aviles E,
Ericson S, Perez EA. The effect of zoledronic acid on aromatase inhibitorassociated bone loss in postmenopausal women with early breast cancer receiving
adjuvant letrozole: the Z-FAST study 5-year final follow-up. Cancer Res. 2009 Dec
15; 69(Suppl 3):733S-4S.
53.
Brufsky A, Bondarenko IN, Smirnov V, Hurvitz S, Perez E, Ponomarova O,
Vynnychenko I, Swamy R, Mu H, Rivera R. RIBBON-2: a randomized, doubleblind, placebo-controlled, phase III trial evaluating the efficacy and safety of
bevacizumab in combination with chemotherapy for second-line treatment of HER2negative metastatic breast cancer. Cancer Res. 2009 Dec 15; 69(Suppl 3):495S-6S.
54.
Palmieri FM, Dueck AC, Johnson DB, Colon-Otero G, Diekmann BB,
Dakhil SR, Franco SX, Reinholz MM, McCullough AE, Rodeheffer RJ, Perez EA.
Cardiac safety of lapatinib given concurrently with paclitaxel and trastuzumab as
part of adjuvant therapy for patients with HER2+breast cancer: pilot data from the
Mayo Clinic Cancer Research Consortium trial RC0639. Cancer Res. 2009 Dec 15;
69(Suppl 3):674S.
55.
Goss PE, Ingle JN, Martino S, Robert N, Muss H, Shepherd L, Pritchard KI,
Livingston RB, Davidson N, Perez EA, Cameron D, Whelan T, Palmer A, Tu D.
Outcomes of women who were premenopausal at diagnosis of early stage breast
cancer in the NCIC CTG MA17 trial. Cancer Res. 2009 Dec 15; 69(Suppl 3):487S.
56.
Perez EA, Reinholz MM, Dueck AC, Tenner KS, Davidson NE, Gralow J,
Harris L, Kutteh L, Jenkins RB, Chen B. Do the ASCO/CAP 2007 HER2 testing
guidelines improve prediction of benefit to adjuvant trastuzumab?: Data from North
Central Cancer Treatment Group N9831 Adjuvant trial. Cancer Res. 2009 Dec 15;
69(Suppl 3):524S.
57.
Hines SL, Sloan JA, Atherton PJ, Perez EA, Dakhil SR, Johnson DB, Reddy
PS, Dalton RJ, Mattar BI, Loprinzi CL. Zoledronic acid for treatment of osteopenia
and osteoporosis in women with primary breast cancer (BC) undergoing adjuvant
aromatase inhibitor (AI) therapy. Cancer Res. 2009 Dec 15; 69(Suppl 3):626S.
58.
Goetz MP, Reinicke KE, Reid JM, Suman VJ, Kuffel MJ, Safgren SL,
Buhrow SA, Reynolds CA, Jenkins RB, Hawse JR, Perez EA, Ingle JN, Ames MM.
Tamoxifen, HER2, and endoxifen: the role of CYP2D6 as a predictor of tamoxifen
resistance in ER+/HER2+breast cancer. Cancer Res. 2009 Dec 15; 69(Suppl
3):594S.
59.
Moreno-Aspitia A, Dueck AC, Patel T, Hillman D, Tenner K, Dakhil SR,
Rowland K, McLaughlin SA, Perez EA, TBCI Breast Cancer Intergroup. Paclitaxelrelated peripheral neuropathy associated with improved outcome of patients with
early stage HER2+breast cancer who did not receive trastuzumab in the N9831
clinical trial. Cancer Res. 2009 Dec 15; 69(24 Suppl 3):625S.
60.
Tan WW, Dueck AC, Flynn P, Steen P, Anderson D, Rowland K, Nothfeldt
D, Lingle W, Copland J, Perez EA. N0539 Phase II Trial of Fulvstrant and
Bevacizumab in Patients with Metastatic Breast Cancer Previouslly Treated with an
Aromatase Inhibitor: A North Central Cancer Treatment Group Trial. Cancer Res.
2009 Dec 15; 69(24 Suppl 3):738S.
61.
Robert N, Dieras V, Glaspy J, Brufsky A, Bondarenko IN, Lipatov O, Perez
E, Yardley D, Phan SC, Bhattacharya S, O'Shaughnessy J. Clinical benefit rate and
time to response in RIBBON-1, a randomized, double-blind, phase III trial of
chemotherapy with or without bevacizumab (B) for the first-line treatment of HER2negative locally recurrent or metastatic breast cancer (MBC). Cancer Res. 2009 Dec
15; 69(Suppl 3):851S.
62.
Reinholz MM, Eckel-Passow J, Anderson K, McCullough A, April C,
Cunningham J, Jen J, Perez EA, Fan JB, Lingle W. Whole genome profiling of
formalin-fixed, paraffin-embedded tissue distinguishes HER2-positive and -negative
breast tumors. Cancer Res. 2009 Dec 15; 69(Suppl 3):865S-6S.
63.
Halyard MY, Pisansky TM, Dueck AC, Suman VJ, Pierce LJ, Solin LJ,
Marks LB, Davidson N, Martino S, Kaufman P, Kutteh L, Dakhil S, Perez EA.
Reply to N. Magne et Al. J Clin Oncol. 2009 Dec 1; 27(34):e240-1 Epub 2009 Nov
2.
64.
Halyard MY, Pisansky TM, Dueck AC, Suman VJ, Pierce LJ, Solin LJ,
Marks LB, Davidson N, Martino S, Kaufman P, Kutteh L, Dakhil S, Perez EA.
Impact on cardiac toxicity with trastuzumab and radiotherapy: the question is still
ongoing. Reply to N. Magne et al. J Clin Oncol. 2009 Dec 1; 27(34):E240-1.
65.
Halyard M, Pisansky TM, Pierce LJ, Solin LJ, Marks LB, Tenner KS, Dueck
AC, Perez EA. Changes in left ventricular function after radiation therapy and
trastuzumab: analysis of North Central Cancer Treatment Group Phase III Trial
N9831. Int J Radiat Oncol Biol Phys. 2009 Nov; 75(3. Suppl 1):S50.
66.
Roy V, Perez EA. Beyond trastuzumab: small molecule tyrosine kinase
inhibitors in HER-2-positive breast cancer. Oncologist. 2009 Nov; 14(11):1061-9.
Epub 2009 Nov 03.
67.
Hines SL, Mincey B, Dentchev T, Sloan JA, Perez EA, Johnson DB,
Schaefer PL, Alberts S, Liu H, Kahanic S, Mazurczak MA, Nikcevich DA, Loprinzi
CL. Immediate versus delayed zoledronic acid for prevention of bone loss in
postmenopausal women with breast cancer starting letrozole after tamoxifenN03CC. Breast Cancer Res Treat. 2009 Oct; 117(3):603-9. Epub 2009 Feb 12.
68.
Dieras V, Glaspy J, Brufsky A, Bondarenko I, Lipatov O, Perez EA, Chan S,
Zhou X, Phan SC, Robert N. Efficacy in patient subgroups in RIBBON-1, a
randomized, double-blind, Phase III trial of chemotherapy with or without
bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or
metastatic breast cancer (MBC). EJC Supplements. 2009 Sep; 7(2):265.
69.
Grant CS, Ingle JN, Suman VJ, Dumesic DA, Wickerham DL, Gelber RD,
Flynn PJ, Weir LM, Intra M, Jones WO, Perez EA, Hartmann LC. Menstrual cycle
and surgical treatment of breast cancer: findings from the NCCTG N9431 study. J
Clin Oncol. 2009 Aug 1; 27(22):3620-6. Epub 2009 Jun 01.
70.
Perez EA. Microtubule inhibitors: Differentiating tubulin-inhibiting agents
based on mechanisms of action, clinical activity, and resistance. Mol Cancer Ther.
2009 Aug; 8(8):2086-95. Epub 2009 Aug 11.
71.
Moreno-Aspitia A, Perez EA. Anthracycline- and/or taxane-resistant breast
cancer: results of a literature review to determine the clinical challenges and current
treatment trends. Clin Ther. 2009 Aug; 31(8):1619-40.
72.
Roy V, Perez EA. Biologic therapy of breast cancer: focus on co-inhibition
of endocrine and angiogenesis pathways. Breast Cancer Res Treat. 2009 Jul;
116(1):31-8. Epub 2008 Dec 20.
73.
Pockaj BA, Degnim AC, Boughey JC, Gray RJ, McLaughlin SA, Dueck
AC, Perez EA, Halyard MY, Frost MH, Cheville AL, Sloan JA. Quality of life after
breast cancer surgery: What have we learned and where should we go next? J Surg
Oncol. 2009 Jun 1; 99(7):447-55.
74.
Halyard MY, Pisansky TM, Dueck AC, Suman V, Pierce L, Solin L, Marks
L, Davidson N, Martino S, Kaufman P, Kutteh L, Dakhil SR, Perez EA.
Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and
adverse event data from the NCCTG Phase III Trial N9831. J Clin Oncol. 2009 Jun
1; 27(16):2638-44. Epub 2009 Apr 06.
75.
Moreno-Aspitia A, Perez EA. Treatment options for breast cancer resistant
to anthracycline and taxane. Mayo Clin Proc. 2009 Jun; 84(6):533-45.
76.
Carney WP, Moreno-Aspitia A, Dueck A, Lingle W, Kutteh L, Tenner K,
Davidson N, Perez E. Serum HER-2/neu levels in early stage HER-2/neu positive
breast cancer (HER-2+BC). Results from the NCCTG adjuvant intergroup trial
N9831. Clin Chem. 2009 Jun; 55(Suppl S):A157.
77.
Apsey H, Roy V, Pockaj B, Northfelt D, Sticca R, Nikcevich DA, Mattar B,
Fitch T, Perez EA. Surgical practice patterns following NCCTG N0338 "Phase II
trial of docetaxel and darboplatin administered every two weeks as induction therapy
for stage II and stage III breast cancer.". J Clin Oncol. 2009 May 20; 27(15s).
Abstract no. 623.
78.
Bernard JR, Vallow LA, McNeil RB, McLaughlin SA, Geiger XJ, Perez EA.
In newly diagnosed breast cancer, is a contralateral prophylactic mastectomy
necessary following a negative MRI? J Clin Oncol. 2009 May 20; 27(15s). Abstract
no. 627.
79.
McCullough A, Dueck A, Chen B, Reinholz M, Wiktor A, Lingle W, Jenkins
R, Perez E. HER-2 central confirmatory testing using ASCO/CAP guidelines for
trastuzumab/lapatinib trial MCCR RC0639. J Clin Oncol. 2009 May 20; 27(15s).
Abstract no. e11527.
80.
Robert NJ, Dieras V, Glaspy J, Brufsky A, Bondarenko I, Lipatov O, Perez
E, Yardley D, Zhou X, Phan S. RIBBON-1: Randomized, double-blind, placebocontrolled, phase III trial of chemotherapy with or without bevacizumab (B) for
first-line treatment of HER2-negative locally recurrent or metastatic breast cancer
(MBC). J Clin Oncol. 2009 May 20; 27(15s). Abstract no. 1005.
81.
Tan W, Allred J, Salim M, Flynn P, Kugler JW, Stella PJ, Wiesenfeld M,
Bernath AM, Fitch TR, Perez EA. N0337: Phase II study of capecitabine in
combination with vinorelbine and trastuzumab for the first or second treatment of
HER2+metastatic breast cancer. J Clin Oncol. 2009 May 20; 27(15s). Abstract no.
1020.
82.
Baselga J, Gianni L, Gradishar WJ, Hudis C, Perez EA, Piccart-Gebhart M,
Schwartzberg LS, Sledge G, Fleming TR. Phase IIb double-blind, randomized,
placebo-controlled trials for the efficacy and safety of sorafenib in patients (pts) with
metastatic or locally advanced breast cancer (BC): Review of the Trials to
Investigate the Effects of Sorafenib in BC (TIES) program. J Clin Oncol. 2009 May
20; 27(15s). Abstract no. e12000.
83.
Sukov WR, Miller DV, Dueck AC, Tenner KS, Jenkins RB, Kaufman PA,
Davidson NE, Dakhil SR, Martino S, Roy V, Perez EA. Benefit of adjuvant
trastuzumab in breast cancer patients with focal HER2 amplified clones: Data from
N9831 Intergroup Adjuvant Trial. J Clin Oncol. 2009 May 20; 27(Suppl S):520.
84.
Moreno-Aspitia A, Hillman DW, Dueck AC, Carney WP, Lingle WL,
Tenner KS, Lafky JM, Reinholz MM, Kutteh LA, Perez EA. Baseline and
recurrence levels of soluble HER2 (sHER2) in early-stage HER2-neu positive breast
cancer (HER2+BC) from the NCCTG adjuvant Intergroup trial N9831. J Clin Oncol.
2009 May 20; 27(15s). Abstract no. 539.
85.
Muss HB, Berry DA, Cirrincione CT, Theodoulou M, Mauer AM, Kornblith
AB, Partridge AH, Dressler LG, Cohen HJ, Becker HP, Kartcheske PA, Wheeler
JD, Perez EA, Wolff AC, Gralow JR, Burstein HJ, Mahmood AA, Magrinat G,
Parker BA, Hart RD, Grenier D, Norton Adjuvant chemotherapy in older women
with early-stage breast cancer. N Engl J Med. 2009 May 14; 360(20):2055-65.
86.
Brufsky AM, Bosserman LD, Caradonna RR, Haley BB, Jones CM, Moore
HC, Jin L, Warsi GM, Ericson SG, Perez EA. Zoledronic acid effectively prevents
aromatase inhibitor-associated bone loss in postmenopausal women with early breast
cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin
Breast Cancer. 2009 May; 9(2):77-85.
87.
Palmieri FM, DePeri ER, Mincey BA, Smith JA, Wen LK, Chewar DM,
Abaya R, Colon-Otero G, Perez EA. Comprehensive diagnostic program for
medically underserved women with abnormal breast screening evaluations in an
urban population. Mayo Clin Proc. 2009 Apr; 84(4):317-22.
88.
Amar S, Roy V, Perez EA. Treatment of metastatic breast cancer: looking
towards the future. Breast Cancer Res Treat. 2009 Apr; 114(3):413-22. Epub 2008
May 09.
89.
Yang P, Mandrekar SJ, Hillman SH, Allen Ziegler KL, Sun Z, Wampfler JA,
Cunningham JM, Sloan JA, Adjei AA, Perez E, Jett JR. Evaluation of glutathione
metabolic genes on outcomes in advanced non-small cell lung cancer patients after
initial treatment with platinum-based chemotherapy: an NCCTG-97-24-51 based
study. J Thorac Oncol. 2009 Apr; 4(4):479-85.
90.
Hines SL, Mincey BA, Sloan JA, Thomas SP, Chottiner E, Loprinzi CL,
Carlson MD, Atherton PJ, Salim M, Perez EA. Phase III randomized, placebocontrolled, double-blind trial of risedronate for the prevention of bone loss in
premenopausal women undergoing chemotherapy for primary breast cancer. J Clin
Oncol. 2009 Mar 1; 27(7):1047-53. Epub 2008 Dec 15.
91.
Perez EA. Impact, mechanisms, and novel chemotherapy strategies for
overcoming resistance to anthracyclines and taxanes in metastatic breast cancer.
Breast Cancer Res Treat. 2009 Mar; 114(2):195-201. Epub 2008 Apr 29.
92.
Reinholz MM, Bruzek AK, Visscher DW, Lingle WL, Schroeder MJ, Perez
EA, Jenkins RB. Breast cancer and aneusomy 17: implications for carcinogenesis
and therapeutic response. Lancet Oncol. 2009 Mar; 10(3):267-77.
93.
Moreno-Aspitia A, Morton RF, Hillman DW, Lingle WL, Rowland KM Jr,
Wiesenfeld M, Flynn PJ, Fitch TR, Perez EA. Phase II trial of sorafenib in patients
with metastatic breast cancer previously exposed to anthracyclines or taxanes: North
Central Cancer Treatment Group and Mayo Clinic Trial N0336. J Clin Oncol. 2009
Jan 1; 27(1):11-5. Epub 2008 Dec 01.
94.
Swain SM, Jeong JH, Geyer CE, Costantino JP, Pajon ER, Fehrenbacher L,
Atkins JN, Polikoff J, Vogel VG, Erban JK, Livingston RB, Perez EA, Mamounas
EP, Ganz PA, Land SR, Wolmark N. NSABP B-30: definitive analysis of patient
outcome from a randomized trial evaluating different schedules and combinations of
adjuvant therapy containing doxorubicin, docetaxel and cyclophosphamide in
women with operable, node-positive breast cancer. Cancer Res. 2009 Jan; 69(2
Suppl S):81S.
95.
Ganz PA, Land SR, Geyer CE, Costantino JP, Pajon ER, Fehrenbacher L,
Atkins JN, Polikoff JA, Vogel VG, Erban JK, Livingston RB, Perez EA, Mamounas
EP, Wolmark A, Swain SM. NSABP B-30: definitive analysis of quality of life
(QOL) and menstrual history (MH) outcomes from a randomized trial evaluating
different schedules and combinations of adjuvant therapy containing doxorubicin,
docetaxel and cyclophosphamide in women with operable, node-positive breast
cancer. Cancer Res. 2009 Jan; 69(2 Suppl S):81S-2S.
96.
Rugo HS, Roche H, Thomas E, Blackwell K, Chung HC, Lerzo G, Volles
LA, Poulart V, Perez E. Ixabepilone plus capecitabine vs capecitabine in patients
with triple negative tumors: a pooled analysis of patients from two large phase III
clinical studies. Cancer Res. 2009 Jan; 69(2 Suppl S):221S-2S.
97.
Pockaj BA, Mukherjee P, Tinder TL, Klosterman CA, Allerd JB, Roy
V, Perez EA. NCCTG N0338: effect of docetaxel and carboplatin on VEGF,
PGE(2), and immune cells in patients with stage II or III breast cancer. Cancer Res.
2009 Jan; 69(2 Suppl S):333S-4S.
98.
Goetz MP, Suman V, Ames M, Black J, Safgren S, Kuffel M, Avula R,
Moyer A, Weinshilboum R, Reynolds C, Perez E, Ingle J. Tamoxifen
pharmacogenetics of CYP2D6, CYP2C19, and SULT1A1: long term follow-up of
the North Central Cancer Treatment Group 89-30-52 adjuvant trial. Cancer Res.
2009 Jan; 69(2 Suppl S):357S-8S.
99.
Conte P, Roche H, Perez E, Sparono J, Xu B, Jassem J, Peck R,
Mukhopadhyay P, Hortobagyi G. Ixabepilone plus capecitabine improves overall
survival in symptomatic patients with metastatic breast cancer previously treated
with anthracycline and taxane in 2 large phase III studies. Cancer Res. 2009 Jan;
69(2 Suppl S):381S-2S.
100.
Dueck AC, Hillman DW, Liu H, Rowland KM, Palmieri FM, Suman
VJ, Perez EA. Comparison of binary efficacy endpoints in 11 North Central Cancer
Treatment Group phase II metastatic breast cancer clinical trials. Cancer Res. 2009
Jan; 69(2 Suppl S):392S.
101.
Tenner KS, Dueck AC, Hillman DW, Rowland KM, Palmieri FM, Suman
VJ, Perez EA. Meta-analysis of adverse event rates in 15 North Central Cancer
Treatment Group phase II metastatic breast cancer clinical trials for the development
of adverse event stopping rules. Cancer Res. 2009 Jan; 69(2 Suppl S):393S.
102.
Johnson BS, Dueck AC, Dakhil SR, Stella PJ, Nikcevich DA, Franco SX,
Wender DB, Schaefer PL, Colon-Otero G, Diekmann BB, Perez EA. Tolerability of
lapatinib given concurrently with paclitaxel and trastuzumab as part of adjuvant
therapy in patients with resected HER2+breast cancer: initial safety data from the
Mayo Clinic cancer research consortium trial RC0639. Cancer Res. 2009 Jan; 69(2
Suppl S):189S-90S.
103.
Perez EA, Palmieri FM, Brock SM. Trastuzumab. Cancer Treat Res. 2009;
151:181-96.
104.
Roy V, Perez EA. Breast cancer. In: Waldman SA, Terzic A, editors.
Pharmacology and therapeutics: principles to practice. Philadelphia:
Saunders/Elsevier; 2009. p. 933-44.
105.
Asmann YW, Klee EW, Thompson EA, Perez EA, Middha S, Oberg AL,
Therneau TM, Smith DI, Poland GA, Wieben ED, Kocher JP. 3' tag digital gene
expression profiling of human brain and universal reference RNA using Illumina
Genome Analyzer. BMC Genomics. 2009; 10:531. Epub 2009 Nov 16.
106.
Soto E, Yanagisawa M, Marlow LA, Copland JA, Perez EA, Anastasiadis
PZ. p120 catenin induces opposing effects on tumor cell growth depending on Ecadherin expression. J Cell Biol. 2008 Nov 17; 183(4):737-49.
107.
Perez EA. Safety of aromatase inhibitors in the adjuvant setting (vol 105,
Suppl 1, pg 75, 2007). Breast Cancer Research & Treatment. 2008 Nov;
112(2):379.
108.
Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A,
Flockhart DA, Hancock B, Davidson N, Gralow J, Dickler M,Perez EA, Cobleigh
M, Shenkier T, Edgerton S, Miller KD, Ecog 2100. Association of vascular
endothelial growth factor and vascular endothelial growth factor receptor-2 genetic
polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus
bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol. 2008 Oct 1;
26(28):4672-8.
109.
Grothey A, Adjei AA, Alberts SR, Perez EA, Jaeckle KA, Loprinzi CL,
Sargent DJ, Sloan JA, Buckner JC, North Central Cancer Treatment Group. North
Central Cancer Treatment Group--achievements and perspectives. Semin Oncol.
2008 Oct; 35(5):530-44.
110.
Goetz MP, Suman VJ, Couch FJ, Ames MM, Rae JM, Erlander MG, Ma XJ,
Sgroi DC, Reynolds CA, Lingle WL, Weinshilboum RM, Flockhart DA, Desta
Z, Perez EA, Ingle JN. Cytochrome P450 2D6 and homeobox 13/interleukin-17B
receptor: combining inherited and tumor gene markers for prediction of tamoxifen
resistance. Clin Cancer Res. 2008 Sep 15; 14(18):5864-8.
111.
Goldstein LJ, O'Neill A, Sparano JA, Perez EA, Shulman LN, Martino S,
Davidson NE. Concurrent doxorubicin plus docetaxel is not more effective than
concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3
positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. J
Clin Oncol. 2008 Sep 1; 26(25):4092-9. Epub 2008 Aug 04.
112.
Goldstein LJ, Gray R, Badve S, Childs BH, Yoshizawa C, Rowley S, Shak S,
Baehner FL, Ravdin PM, Davidson NE, Sledge GW Jr, Perez EA, Shulman LN,
Martino S, Sparano JA. Prognostic utility of the 21-gene assay in hormone receptorpositive operable breast cancer compared with classical clinicopathologic features. J
Clin Oncol. 2008 Sep 1; 26(25):4063-71. Epub 2008 Aug 04.
113.
Hines SL, Vallow LA, Tan WW, McNeil RB, Perez EA, Jain A. Clinical
outcomes after a diagnosis of brain metastases in patients with estrogen- and/or
human epidermal growth factor receptor 2-positive versus triple-negative breast
cancer. Ann Oncol. 2008 Sep; 19(9):1561-5. Epub 2008 Jun 05.
114.
Perez EA, Suman VJ. Lack of publication bias related to results from
trastuzumab study. Lancet. 2008 Aug 23; 372(9639):626-7.
115.
Regan MM, Pagani O, Walley B, Torrisi R, Perez EA, Francis P, Fleming
GF, Price KN, Thurlimann B, Maibach R, Castiglione-Gertsch M, Coates AS,
Goldhirsch A, Gelber RD, SOFT/TEXT/PERCHE Steering Committee,
International Breast Cancer Study Group. Premenopausal endocrine-responsive
early breast cancer: who receives chemotherapy? Ann Oncol. 2008 Jul; 19(7):123141. Epub 2008 Mar 05.
116.
Perez EA, Baweja M. HER2-positive breast cancer: current treatment
strategies. Cancer Invest. 2008 Jul; 26(6):545-52.
117.
Perez EA, Koehler M, Byrne J, Preston AJ, Rappold E, Ewer MS. Cardiac
safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo
Clin Proc. 2008 Jun; 83(6):679-86.
118.
Badve SS, Baehner FL, Gray RP, Childs BH, Maddala T, Liu ML, Rowley
SC, Shak S, Perez EA, Shulman LJ, Martino S, Davidson NE, Sledge GW,
Goldstein LJ, Sparano JA. Estrogen- and progesterone-receptor status in ECOG
2197: comparison of immunohistochemistry by local and central laboratories and
quantitative reverse transcription polymerase chain reaction by central laboratory. J
Clin Oncol. 2008 May 20; 26(15):2473-81.
119.
Ingle JN, Tu D, Pater JL, Muss HB, Martino S, Robert NJ, Piccart MJ,
Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton
L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Goss PE. Intent-to-treat
analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in
early breast cancer: NCIC CTG MA.17. Ann Oncol. 2008 May; 19(5):877-82. Epub
2008 Mar 10.
120.
Shah SS, Ketterling RP, Perez EA, Chen BY. Impact of American Society
of Clinical Oncology/College of American Pathologists guideline recommendations
on HER2 testing in breast cancer. Virchows Arch. 2008 May; 452(Suppl 1):S23-4.
121.
Johnson EA, Marks RS, Mandrekar SJ, Hillman SL, Hauge MD, Bauman
MD, Wos EJ, Moore DF, Kugler JW, Windschitl HE, Graham DL, Bernath AM Jr,
Fitch TR, Soori GS, Jett JR, Adjei AA, Perez EA. Phase III randomized, doubleblind study of maintenance CAI or placebo in patients with advanced non-small cell
lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51). Lung
Cancer. 2008 May; 60(2):200-7. Epub 2007 Nov 28.
122.
Amar S, Moreno-Aspitia A, Perez EA. Issues and controversies in the
treatment of HER2 positive metastatic breast cancer. Breast Cancer Res Treat. 2008
May; 109(1):1-7. Epub 2007 Jul 26.
123.
Brufsky A, Bundred N, Coleman R, Lambert-Falls R, Mena R, Hadji P, Jin
L, Schenk N, Ericson S, Perez EA, Z-FAST and ZO-FAST Study Groups.
Integrated analysis of zoledronic acid for prevention of aromatase inhibitorassociated bone loss in postmenopausal women with early breast cancer receiving
adjuvant letrozole. Oncologist. 2008 May; 13(5):503-14.
124.
Perez EA. The Sledge article reviewed. Adjuvant therapy for breast cancer:
current approaches and strategies for a better future. Oncology. 2008 May;
22(6):606,.
125.
Goss PE, Ingle JN, Pater JL, Martino S, Robert NJ, Muss HB, Piccart MJ,
Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton
L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Tu D. Late extended adjuvant
treatment with letrozole improves outcome in women with early-stage breast cancer
who complete 5 years of tamoxifen. J Clin Oncol. 2008 Apr 20; 26(12):1948-55.
Epub 2008 Mar 10.
126.
Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, Wolff AC,
Sledge GW Jr, Wood WC, Davidson NE. Weekly paclitaxel in the adjuvant
treatment of breast cancer. N Engl J Med. 2008 Apr 17; 358(16):1663-71.
127.
Brufsky A, Bosserman L, Caradonna R, Haley B, Jones M, Moore H, Dong
M, Warsi G, Ericson S, Perez E. Zoledronic acid (ZA) prevents aromatase inhibitor
(AI)-associated bone loss in postmenopausal women with early breast cancer 36month follow-up of the Z-FAST study. Ejc Supplements. 2008 Apr; 6(7):197.
128.
Perez EA, Suman VJ, Davidson NE, Sledge GW, Kaufman PA, Hudis CA,
Martino S, Gralow JR, Dakhil SR, Ingle JN, Winer EP, Gelmon KA, Gersh BJ, Jaffe
AS, Rodeheffer RJ. Cardiac safety analysis of doxorubicin and cyclophosphamide
followed by paclitaxel with or without trastuzumab in the North Central Cancer
Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol. 2008 Mar 10;
26(8):1231-8. Epub 2008 Feb 04.
129.
Perez EA. Cardiac toxicity of ErbB2-targeted therapies: what do we know?
Clin Breast Cancer. 2008 Mar; 8 Suppl 3:S114-20.
130.
Gralow J, Rugo H, Gradishar W, O'Shaughnessy JA, Jahanzeb M, Perez E,
Tripathy D. Novel taxane formulations in the treatment of breast cancer: a thought
leader discussion and consensus roundtable. Clin Breast Cancer. 2008 Feb; 8(1):33-
7.
131.
Visscher DW, Reinholtz M, Hillman D, Jenkins R, Perez E. Analysis of
staining heterogeneity and level of amplification in breast carcinomas with "2+"
HER-2 immunoreactivity. Mod Pathol. 2008 Jan; 21(Suppl 1):58A.
132.
Visscher DW, Reinholtz M, Hillman D, Jenkins R, Perez E. Analysis of
staining heterogeneity and level of amplification in breast carcinomas with "2+"
HER-2 immunoreactivity. Lab Invest. 2008 Jan; 88(Suppl 1):58A.
133.
Perez EA. Modulating drug resistance in metastatic breast cancer.
Community Oncol. 2008; 5(4 SUPPL. 3):2-9.
134.
Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier
T, Cella D, Davidson NE. Paclitaxel plus bevacizumab versus paclitaxel alone for
metastatic breast cancer. N Engl J Med. 2007 Dec 27; 357(26):2666-76.
135.
Reinholz MM, Jenkins RB, Hillman D, Lingle WL, Davidson N, Martino S,
Kaufman P, Kutteh L, Perez EA. The clinical significance of polysomy 17 in the
HER2+N9831 intergroup adjuvant trastuzumab trial. Breast Cancer Res Treat. 2007
Dec; 106(Suppl 1):S11-2.
136.
Miller KD, Oneill A, Perez EA, Seidman AD, Sledge GW. Phase II
feasibility trial incorporating bevacizumab into dose dense doxorubicin and
cyclophosphamide followed by paclitaxel in patients with lymph node positive
breast cancer: a trial of the Eastern Cooperative Oncology Group (E2104). Breast
Cancer Res Treat. 2007 Dec; 106(Suppl 1):S147.
137.
Vallow L, Hines S, Jain A, Tan W, Buskirk S, Perez EA. Estrogen receptor
status: a prognostic predictor of outcome in HER-2 positive breast cancer with brain
metastases. Breast Cancer Res Treat. 2007 Dec; 106(Suppl 1):S171-2.
138.
Reinholz MM, Kitzmann KK, Hillman D, Lingle WL, Hobday T, Moreno A,
Vivek R, Perez EA. Differential gene expression in circulating tumor cells between
primary and metastatic breast cancer patients. Breast Cancer Res Treat. 2007 Dec;
106(Suppl 1):S213-4.
139.
Hines SL, Vallow L, Tan W, Jain A, Perez E. Clinical outcome of patients
with triple negative (TN) breast cancer who develop brain metastasis. Breast Cancer
Res Treat. 2007 Dec; 106(Suppl 1):S252-3.
140.
Palmieri FM, DePeri ER, Mincey BA, Smith JA, Wen LK, Cheivar
DM, Perez EA. A comprehensive diagnostic program for medically underserved
women with abnormal breast screening evaluations in an urban population. Breast
Cancer Res Treat. 2007 Dec; 106(Suppl 1):S261.
141.
Gabrilove JL, Perez EA, Tomita DK, Rossi G, Cleeland CS. Assessing
symptom burden using the M. D. Anderson symptom inventory in patients with
chemotherapy-induced anemia: results of a multicenter, open-label study
(SURPASS) of patients treated with darbepoetin-alpha at a dose of 200 microg
every 2 weeks. Cancer. 2007 Oct 1; 110(7):1629-40.
142.
Perez EA. Safety profiles of tamoxifen and the aromatase inhibitors in
adjuvant therapy of hormone-responsive early breast cancer. Ann Oncol. 2007 Sep;
18 Suppl 8:viii26-35.
143.
Pruthi S, Boughey JC, Brandt KR, Degnim AC, Dy GK, Goetz MP, Perez
EA, Reynolds CA, Schomberg PJ, Ingle JN. A multidisciplinary approach to the
management of breast cancer, part 2: therapeutic considerations. Mayo Clin Proc.
2007 Sep; 82(9):1131-40.
144.
Perez EA, Lerzo G, Pivot X, Thomas E, Vahdat L, Bosserman L, Viens P,
Cai C, Mullaney B, Peck R, Hortobagyi GN. Efficacy and safety of ixabepilone
(BMS-247550) in a phase II study of patients with advanced breast cancer resistant
to an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2007 Aug 10;
25(23):3407-14. Epub 2007 Jul 02.
145.
Garrison LP Jr, Lubeck D, Lalla D, Paton V, Dueck A, Perez EA. Cost-
effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-
positive breast cancer. Cancer. 2007 Aug 1; 110(3):489-98.
146.
Amar S, Roy V, Perez EA. Letrozole: present and future role in the
treatment of breast cancer. Expert Opin Pharmacother. 2007 Aug; 8(12):1965-75.
147.
Pruthi S, Brandt KR, Degnim AC, Goetz MP, Perez EA, Reynolds CA,
Schomberg PJ, Dy GK, Ingle JN. A multidisciplinary approach to the management
of breast cancer, part 1: prevention and diagnosis. Mayo Clin Proc. 2007 Aug;
82(8):999-1012.
148.
Perez EA. Novel enhanced delivery taxanes: an update. Semin Oncol. 2007
Jun; 34(3):suppl 1-5.
149.
Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione
M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton
L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL, National Cancer
Institute of Canada Clinical Trials Efficacy of letrozole extended adjuvant therapy
according to estrogen receptor and progesterone receptor status of the primary
tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. J Clin
Oncol. 2007 May 20; 25(15):2006-11. Epub 2007 Apr 23.
150.
Halyard MY, Jatoi A, Sloan JA, Bearden JD 3rd, Vora SA, Atherton
PJ, Perez EA, Soori G, Zalduendo AC, Zhu A, Stella PJ, Loprinzi CL. Does zinc
sulfate prevent therapy-induced taste alterations in head and neck cancer patients?
Results of phase III double-blind, placebo-controlled trial from the North Central
Cancer Treatment Group (N01C4). Int J Radiat Oncol Biol Phys. 2007 Apr 1;
67(5):1318-22.
151.
Brufsky A, Harker WG, Beck JT, Carroll R, Tan-Chiu E, Seidler C,
Hohneker J, Lacerna L, Petrone S, Perez EA. Zoledronic acid inhibits adjuvant
letrozole-induced bone loss in postmenopausal women with early breast cancer. J
Clin Oncol. 2007 Mar 1; 25(7):829-36.
152.
Hines SL, Tan WW, Yasrebi M, DePeri ER, Perez EA. The role of
mammography in male patients with breast symptoms. Mayo Clin Proc. 2007 Mar;
82(3):297-300.
153.
Piccart-Gebhart MJ, Perez EA, Baselga J, Gelber RD, Rosa D, Azambuja E,
Oliva C, Goldhirsch A. ALTTO (adjuvant lapatinib and/or trastuzumab treatment
optimisation) study [BIG 2-06/N063D/EGF106708]: a phase III study for HER2overexpressing early breast cancer (BC) (Abstract # P118). Breast. 2007 Mar;
16(Suppl 1):S46-7.
154.
Ewer MS, Perez EA, Baselga J, Bell R, Brutsaert D, Marty M, Pienkowski
T, Suter TM. Cardiac safety guidelines for the adjuvant use of trastuzumab
(Herceptin®) in HER2-positive early breast cancer (Abstract #P176). Breast. 2007
Mar; 16(Suppl 1):S63.
155.
Palmieri FM, Perez EA. Managing high-risk breast cancer. Semin Oncol
Nurs. 2007 Feb; 23(1):29-36.
156.
Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ,
Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram
MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH,
van de Vijver M, Wheeler TM, Hayes DF, American Society of Clinical
Oncology/College of American Pathologists guideline recommendations for human
epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007 Jan
1; 25(1):118-45. Epub 2006 Dec 11.
157.
Goetz MP, Knox SK, Suman VJ, Rae JM, Safgren SL, Ames MM, Visscher
DW, Reynolds C, Couch FJ, Lingle WL, Weinshilboum RM, Fritcher EG, Nibbe
AM, Desta Z, Nguyen A, Flockhart DA, Perez EA, Ingle JN. The impact of
cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast
Cancer Res Treat. 2007 Jan; 101(1):113-21. Epub 2006 Nov 18.
158.
Perez EA. Safety of aromatase inhibitors in the adjuvant setting. Breast
Cancer Res Treat. 2007; 105 Suppl 1:75-89. Epub 2007 Oct 03.
159.
Perez EA. Appraising adjuvant aromatase inhibitor therapy. Oncologist.
2006 Nov-Dec; 11(10):1058-69.
160.
Ingle JN, Tu D, Pater JL, Martino S, Robert NJ, Muss HB, Piccart MJ,
Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton
L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Goss PE. Duration of letrozole
treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended
adjuvant therapy trial. Breast Cancer Res Treat. 2006 Oct; 99(3):295-300. Epub
2006 Mar 16.
161.
Perez EA. The balance between risks and benefits: Long-term use of
aromatase inhibitors. European Journal of Cancer Supplement 1990 2006 Sep;
4(9):16-25.
162.
Goetz MP, Rae JM, Safgren SL, Ames MM, Visscher DW, Reynolds C,
Couch F, Lingle WL, Flockhart DA, Desta Z, Perez EA, Ingle JN. Polymorphism in
the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot
flashes: Data from the Italian tamoxifen trial - Reply. J Clin Oncol. 2006 Aug 1;
24(22):3709.
163.
Perez EA, Josse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP,
Shenkier TN, Tozer RG, Palmer MJ, Shepherd LE, Liu S, Tu D, Goss PE. Effect of
letrozole versus placebo on bone mineral density in women with primary breast
cancer completing 5 or more years of adjuvant tamoxifen: a companion study to
NCIC CTG MA.17. J Clin Oncol. 2006 Aug 1; 24(22):3629-35. Epub 2006 Jul 05.
164.
Perez EA, Weilbaecher K. Aromatase inhibitors and bone loss. Oncology
(Williston Park) 2006 Aug; 20(9):1029-39; discussion 1039-40, 1042, 1048.
165.
Perez EA, Suman VJ, Davidson NE, Martino S, Kaufman PA, Lingle WL,
Flynn PJ, Ingle JN, Visscher D, Jenkins RB. HER2 testing by local, central, and
reference laboratories in specimens from the North Central Cancer Treatment Group
N9831 intergroup adjuvant trial. J Clin Oncol. 2006 Jul 1; 24(19):3032-8.
166.
Ingle JN, Suman VJ, Mailliard JA, Kugler JW, Krook JE, Michalak JC,
Pisansky TM, Wold LE, Donohue JH, Goetz MP, Perez EA. Randomized trial of
tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in
postmenopausal women with resected estrogen receptor positive breast cancer.
North Central Cancer Treatment Group Trial 89-30-52. Breast Cancer Res Treat.
2006 Jul; 98(2):217-22. Epub 2006 Mar 15.
167.
Garrison LP Jr, Perez EA, Dueck A, Lalla D, Paton V, Lubeck D. Cost-
effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2+
breast cancer J Clin Oncol. 2006 Jun 20; 24(182):306s. Abstract no. 6023.
168.
Halyard MY, Pisansky TM, Solin LJ, Marks LB, Pierce LJ, Dueck A, Perez
EA. Adjuvant radiotherapy (RT) and trastuzumab in stage I-IIA breast cancer:
toxicity data from North Central Cancer Treatment Group Phase III trial N9831 J
Clin Oncol. 2006 Jun 20; 24(18S):8s. Abstract no. 523.
169.
Ellis GK, Green SJ, Russell CA, Royce ME, Perez EA, Livingston RB.
SWOG 0012, a randomized phase III comparison of standard doxorubicin and
cyclophosphamide followed by weekly paclitaxel versus weekly doxorubicin and
daily oral cyclophosphamide plus G-CSF followed by weekly paclitaxel as
neoadjuvant therapy for inflammatory and locally advanced breast cancer (Abstract
LBA537). J Clin Oncol. 2006 Jun; 24(18S):12s.
170.
Mincey B, Duh M, Moyneur E, Marynchencko M, Boyce S, Perez E. Risk
of cancer treatment-related osteoporosis and fractures among women with breast
cancer receiving aromatase inhibitors (Abstract 557). J Clin Oncol. 2006 Jun;
24(18S):17s.
171.
Lambert-Falls R, Deutsch MA, Desch C, Zhou K, Perez E. Phase III
adjuvant trial of concurrent epirubicin/taxane vs. sequential
epirubicin/cyclophosphamide followed by taxane for node positive breast cancer
(Abstract 573). J Clin Oncol. 2006 Jun; 24(18S):21s.
172.
Moreno-Aspitia A, Hillman DW, Wiesenfeld M, Hobday TJ, Rowland KM,
Northfelt DW, Tenner KS, Palmieri FM, Perez EA. BAY 43-9006 as single oral
agents in patients with metastatic breast cancer previously exposed to anthracycline
and/or taxane (Abstract 577). J Clin Oncol. 2006 Jun; 24(18S):22s.
173.
Vallow LA, Packianathan S, Deperi ER, McDonough MD, Earle JD, Perez
EA. Pre-operative breast magnetic resonance imaging (MRI) influences patient
selection for partial breast irradiation (Abstract 604). J Clin Oncol. 2006 Jun;
24(18S):28s.
174.
Thomas E, Perez EA, Mukhopadhyay P, Lerzo G, Pivot X, Bosserman LD,
Mullaney B, Vahdat L, Hortobagyi GM. Phase II trial of ixabepilone in patients with
metastatic breast cancer (MBC) who are resistant to an anthracycline, a taxane and
capecitabine (Abstract 660). J Clin Oncol. 2006 Jun; 24(18S):42s.
175.
Hillman SL, Mandrekar SJ, Bot BM, Perez EA, Kugler JW, Adjei AA,
Buckner JC, Sargent DJ. Should attribution be considered when interpreting adverse
event data: a North Central Cancer Treatment Group (NCCTG) evaluation of a
phase III placebo controlled trial (Abstract 6006). J Clin Oncol. 2006 Jun;
24(18S):302s.
176.
Yang P, Mandrekar SJ, Hillman SL, Allen KL, Sun Z, Wampfler J,
Cunningham JM, Jett JR, Adjei AA, Perez EA. Evaluation of platinum-based
chemotherapy, glutathione metabolic genes, and survival in advanced non small cell
lung cancer: a NCCTG 97-24-51 based study (Abstract 13013). J Clin Oncol. 2006
Jun; 24(18S):603s.
177.
Perez EA, Sledge GW. Evolving treatment options for patients with
metastatic breast cancer - Introduction. Semin Oncol. 2006 Jun; 33(3 Suppl 9):S1S2.
178.
Roy V, Perez EA. New therapies in the treatment of breast cancer. Semin
Oncol. 2006 Jun; 33(3 Suppl 9):S3-8.
179.
Mincey BA, Duh MS, Thomas SK, Moyneur E, Marynchencko M, Boyce
SP, Mallett D, Perez EA. Risk of cancer treatment-associated bone loss and
fractures among women with breast cancer receiving aromatase inhibitors. Clin
Breast Cancer. 2006 Jun; 7(2):127-32.
180.
Ellis GK, Barlow WE, Russell CA, Royce ME, Perez EA, Livingston RB.
SWOG 0012, a randomized phase III comparison of standard doxorubicin (A) and
cyclophosphamide (C) followed by weekly paclitaxel (T) versus weekly doxorubicin
and daily oral cyclophosphamide plus G-CSF (G) followed by weekly paclitaxel as
neoadjuvant therapy for inflammatory and locally advanced breast cancer (Abstract
LBA537). J Clin Oncol. 2006 Jun; 24(Part II of II No. 18S):933s.
181.
Berry DA, Cirrincione C, Henderson IC, Citron ML, Budman DR, Goldstein
LJ, Martino S, Perez EA, Muss HB, Norton L, Hudis C, Winer EP. Estrogenreceptor status and outcomes of modern chemotherapy for patients with nodepositive breast cancer. JAMA. 2006 Apr 12; 295(14):1658-67.
182.
Goetz MP, Suman VJ, Ingle JN, Nibbe AM, Visscher DW, Reynolds CA,
Lingle WL, Erlander M, Ma XJ, Sgroi DC, Perez EA, Couch FJ. A two-gene
expression ratio of homeobox 13 and interleukin-17B receptor for prediction of
recurrence and survival in women receiving adjuvant tamoxifen. Clin Cancer Res.
2006 Apr 1; 12(7 Pt 1):2080-7.
183.
Perez EA, Forbes JF. From tamoxifen to letrozole: Changing paradigms for
the treatment of hormone-sensitive breast cancer - Introduction. Semin Oncol. 2006
Apr; 33(2 Suppl 7):S1.
184.
Baweja M, Suman VJ, Fitch TR, Mailliard JA, Bernath A, Rowland KM,
Alberts SR, Kaur JS, Perez EA, Ncctg. Phase II trial of oral vinorelbine for the
treatment of metastatic breast cancer in patients > or = 65 years of age: an NCCTG
study. Ann Oncol. 2006 Apr; 17(4):623-9. Epub 2006 Mar 06.
185.
Ingle JN, Suman VJ, Rowland KM, Mirchandani D, Bernath AM,
Camoriano JK, Fishkin PA, Nikcevich DA, Perez EA, North Central Cancer
Treatment Group Trial N0032. Fulvestrant in women with advanced breast cancer
after progression on prior aromatase inhibitor therapy: North Central Cancer
Treatment Group Trial N0032. J Clin Oncol. 2006 Mar 1; 24(7):1052-6.
186.
Carlson RW, Brown E, Burstein HJ, Gradishar WJ, Hudis CA, Loprinzi C,
Mamounas EP, Perez EA, Pritchard K, Ravdin P, Recht A, Somlo G, Theriault RL,
Winer EP, Wolff AC, National Comprehensive Cancer Network. NCCN Task Force
Report: Adjuvant Therapy for Breast Cancer. J Natl Compr Canc Netw. 2006 Mar; 4
Suppl 1:S1-26.
187.
Zon R, Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez E,
Shenkier T, Davidson N. A randomized phase III trial of paclitaxel with or without
bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer:
Eastern Cooperative Oncology Group trial E2100 (Abstract 7). EJC. 2006 Mar; 4(2
Suppl):47.
188.
Perez EA, Halyard M, Pisansky T, Suman VJ, Dueck A, Davidson N,
Martino S, Kaufman P. Radiotherapy concurrent with trastuzumab is well tolerated
in the adjuvant treatment of women with HER2-positive breast cancer: cardiac
safety data from the NCCTG N9831 study (Abstract 226). EJC. 2006 Mar; 4(2
Suppl):113.
189.
Bryant J, Romond E, Perez EA. Trastuzumab in breast cancer - Reply. N
Engl J Med. 2006 Feb 9; 354(6):643.
190.
Roy V, Perez EA. Adjuvant docetaxel plus doxorubicin and
cyclophosphamide increases survival compared with fluorouracil plus doxorubicin
and cyclophosphamide in women with operable node-positive breast cancer. Cancer
Treat Rev. 2006 Feb; 32(1):55-8. Epub 2006 Jan 19.
191.
Wirk B, Perez E. Role of gemcitabine in breast cancer management: an
update. Semin Oncol. 2006 Feb; 33(1 Suppl 2):S6-14.
192.
Ma CX, Steen P, Rowland KM, Niedringhaus RD, Fitch TR, Kugler JW,
Hillman DW, Perez EA, Ingle JN, Adjei AA. A phase II trial of a combination of
pemetrexed and gemcitabine in patients with metastatic breast cancer: an NCCTG
study. Ann Oncol. 2006 Feb; 17(2):226-31. Epub 2005 Nov 22.
193.
Baselga J, Perez EA, Pienkowski T, Bell R. Adjuvant trastuzumab: a
milestone in the treatment of HER-2-positive early breast cancer. Oncologist. 2006;
11 Suppl 1:4-12.
194.
Halyard MY, Jatoi A, Sloan JA, Bearden JD, Fitch TR, Atherton PJ, Buskirk
SJ, Soori GS, Kugler JW, Loprinzi CL. Does zinc sulfate to prevent radiationinduced taste alterations ("dysgeusia") in head and neck cancer patients? A North
Central Cancer Treatment Group (NCCTG) placebo-controlled trial (N01C4)
(Abstract 2367). Int J Radiat Oncol Biol Phys. 2006; 66(3 Suppl):S414.
195.
Goetz MP, Suman V, Couch F, Ames M, Rae J, Erlander M, Knox S, Ma XJ,
Reynolds C, Visscher D, Lingle W, Flockhart D, Desta Z, Sgroi D, Goss P, Perez E,
Ingle J. An index based on HOXB13/IL17BR and CYP2D6 for determination of
relapse and survival in tamoxifen-treated node negative breast cancer. Breast Cancer
Res Treat. 2006; 100(Suppl 1):S53.
196.
Hines SL, Tan W, Yasrebi M, DePeri E, Feigel DG, Perez EA. The role of
mammography in male patients with breast symptoms (Abstract 408). Breast
Cancer. 2006; 100(Suppl 1):S34.
197.
Perez EA, Hillman DW, Kugler JW, Steen PD, Fitch TR, Rowland KM.
North Central cancer treatment group (NCCTG) N0432: phase II trial of docetazel
with capecitabine and bevacizumab as first line chemotherapy for patients with
metastatic breast cancer (Abstract 2069). Breast Cancer. 2006; 100(Suppl 1):S104.
198.
Deutsch M, Lambert Falls R, Desch C, Zhou K, Perez E. Epirubicin
combined with docetaxel or paclitaxel for node positive breast cancer, an
exploratory analysis from a phase III study (Abstract 2103). Breast Cancer. 2006;
100(Suppl 1):S115.
199.
Vallow LA, Packianathan S, DePeri ER, McDonough MD, Perez EA. The
use of magnetic resonance imaging (MRI) in patient selection for partial breast
irradiation (Abstract 4093). Breast Cancer. 2006; 100(Suppl 1):S202.
200.
Martin AM, Platek G, Perez EA, Xue Z, St Jean P, Akkari PA, Nelson M,
Stein S, Gilmer TM, Cable L, Byrne J, Zaks TZ. Pharmacogenetics of cardiac
dysfunction in individuals treated with TYKERB: a case-control study (Abstract
6097). Breast Cancer. 2006; 100(Suppl 1):S288.
201.
Perez EA, Enui AE. Molecular profiling in breast cancer. In: Piccart MJ, et
al, editors. Breast cancer and molecular medicine. Berlin: Springer; 2006. p. 9771006.
202.
Perez EA. Anti-HER2 monoclonal antibody therapy with adjuvant
chemotherapy for breast cancer. Ann Oncol. 2006; 17(Suppl 9):39.
203.
Perez EA, Byrne JA, Hammond IW, Rafi R, Martin AM, Berger MS, Zaks
TZ, Oliva CR, Roychowdhury DF, Stein SH. Cardiac safety experience in 3127
patients (PTS) treated with lapatinib. Ann Oncol. 2006; 17(Suppl 9):70.
204.
Pivot X, Thomas E, Lerzo G, Bosserman L, Vahdat L, Cai C, Mullaney B,
Viens P, Perez E, Hortobagyi GN. Ixabepilone in patients (PTS) with metastatic
breast cancer (MBC) that is resistant to an anthracycline, a taxane and capecitabine.
Ann Oncol. 2006; 17(Suppl 9):70-1.
205.
Roche H, Perez EA, Llombart-Cussac A, Pivot X, Thomas E, Baselga J,
Gianni L, Poulart V, Peck R, Martin M. Ixabepilone, an epothilone B analog, is
effective in Er, Pr, Her-2 negative (triple negative) patients (PTS): Data from
neoadjuvant and metastatic breast cancer (MBC) trials. Ann Oncol. 2006; 17(Suppl
9):97-8.
206.
Perez EA. Other significant research and future directions. Clinical
Advances in Hematology and Oncology. 2006; 4(3 Suppl 7):8-9.
207.
Slamon DJ, Romond EH, Perez EA. Advances in adjuvant therapy for breast
cancer. Clinical Advances in Hematology and Oncology. 2006; 4(3 Suppl 7):1.
208.
Jatoi A, Hillman S, Stella P, Green E, Adjei A, Nair S, Perez E, Amin B,
Schild SE, Castillo R, Jett JR. Should elderly non-small-cell lung cancer patients be
offered elderly-specific trials? Results of a pooled analysis from the North Central
Cancer Treatment Group. J Clin Oncol. 2005 Dec 20; 23(36):9113-9.
209.
Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW,
Reynolds C, Couch FJ, Lingle WL, Flockhart DA, Desta Z,Perez EA, Ingle JN.
Pharmacogenetics of tamoxifen biotransformation is associated with clinical
outcomes of efficacy and hot flashes. J Clin Oncol. 2005 Dec 20; 23(36):9312-8.
210.
Perez EA. Advances in combination chemotherapy in metastatic breast
cancer. European Journal of Cancer Supplement 1990 2005 Dec; 3(5):1.
211.
Perez EA, Suman VJ, Rowland KM, Ingle JN, Salim M, Loprinzi CL, Flynn
PJ, Mailliard JA, Kardinal CG, Krook JE, Thrower AR, Visscher DW, Jenkins RB.
Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or
every-3-week schedule) as first-line therapy in women with HER2-overexpressing
metastatic breast cancer: NCCTG study 983252. Clin Breast Cancer. 2005 Dec;
6(5):425-32.
212.
Perez E, Muss HB. Optimizing adjuvant chemotherapy in early-stage breast
cancer. Oncology (Williston Park). 2005 Dec; 19(14):1759-67; discussion 1768,
1772-4, 1777-8.
213.
Moreno-Aspitia A, Perez EA. Nanoparticle albumin-bound paclitaxel (ABI-
007): a newer taxane alternative in breast cancer. Future Oncol. 2005 Dec; 1(6):75562.
214.
Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE,
Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM,
Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB,
Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Trastuzumab plus adjuvant
chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005 Oct
20; 353(16):1673-84.
215.
Eniu A, Palmieri FM, Perez EA. Weekly administration of docetaxel and
paclitaxel in metastatic or advanced breast cancer. Oncologist. 2005 Oct; 10(9):66585.
216.
Moreno-Aspitia A, Perez EA. North Central Cancer Treatment Group
N0531: phase II trial of weekly albumin-bound paclitaxel (ABI-007; Abraxane) in
combination with gemcitabine in patients with metastatic breast cancer. Clin Breast
Cancer. 2005 Oct; 6(4):361-4.
217.
Romond EH, Perez EA, Bryant J, Suman V, Geyer CE, Davidson N, Paik S,
Martino S, Kaufman P, Wolmark N. Doxorubicin and cyclophosphamide (AC)
followed by paclitaxel (T) with or without trastuzumab (H) as adjuvant therapy for
patients with HER2-positive operable breast cancer (BC): combined analysis of
NSABP B-31 and NCCTG N9831 (Abstract 263). EJC. 2005 Oct; 3(2):73.
218.
Perez E, Suman VJ, Davidson N, Martino S, Kaufman P. Concurrent
trastuzumab and paclitaxel treatment improves disease-free survival in resected
HER2-positive breast cancer: NCCTG N9831 interim analysis (Abstract 264). EJC.
2005 Oct; 3(2):74.
219.
Miller K, Wang M, Gralow J, Dickler M, Cobleigh MA, Perez EA, Shenkier
TN, Davidson NE. First-line bevacizumab and paclitaxel in patients with locally
recurrent or metastatic breast cancer: a randomized phase III trial coordinated by the
Eastern Cooperative Oncology Group (E3100) (Abstract 275). EJC. 2005 Oct;
3(2):77-8.
220.
Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione
M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton
L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL. Randomized trial of
letrozole following tamoxifen as extended adjuvant therapy in receptor-positive
breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005
Sep 7; 97(17):1262-71.
221.
Perez EA. TAC-a new standard in adjuvant therapy for breast cancer? N
Engl J Med. 2005 Jun 2; 352(22):2346-8.
222.
Citron ML, Berry DA, Cirrincione C, Livingston RB, Gradishar W, Perez E,
Muss H, Norton L, Winer E, Hudis C. Dose-dense (DD) AC followed by paclitaxel
is associated with moderate, frequent anemia compared to sequential (S) and/or less
DD treatment: update by CALGB on Breast Cancer Intergroup Trial C9741 with
ECOG, SWOG, & NCCTG J Clin Oncol. 2005 Jun 1; 23(16S part I):33s. Abstract
no. 620.
223.
Boyce SP, Mincey BA, Duh MS, Marynchenko M, Raut MK, Brandman
J, Perez EA. Risk of osteoporosis/osteopenia among women with breast cancer
receiving anti-cancer therapy (ACT) (Abstract 665). J Clin Oncol. 2005 Jun; 23(16S
part I):44S.
224.
Baweja M, Suman V, Fitch TR, Mailliard JA, Bernath A, Rowland KM,
Alberts SR, Kaur JS, Perez EA. Phase II trial of oral vinorelbine for treatment of
metastatic breast cancer in women 65 years and older: NOO3A (Abstract 740). J
Clin Oncol. 2005 Jun; 23(16S part I):63S.
225.
Johnson EA, Marks RS, Mandrekar S, Hillman S, Mailliard J, Dentchev T,
Reuter N, Jett J, Perez EA. A phase III randomized placebo controlled NCCTG trial
of carboxyaminoimidazole (CAI) in patients with advanced non-small cell lung
cancer (NSCLC) (Abstract 7054). J Clin Oncol. 2005 Jun; 23(16S part I):634s.
226.
Goldstein LJ, O'Neill A, Sparano J, Perez E, Shulman L, Martino S,
Davidson N. E2197: phase III AT (doxorubicin/docetaxel) vs. AC
(doxorubicin/cyclophosphamide) in the adjuvant treatment of node positive and high
risk node negative breast cancer (Abstract 512). J Clin Oncol. 2005 Jun; 23(16S part
1):7S.
227.
Vukelja S, O'Shaughnessy J, Campos S, Vahdat L, Blum J, Yardley D,
Mainwaring P, Senecal F, Benner R, Denis L, Perez E. Activity of oral irinotecan
(IRI) in metastatic breast cancer (MBC) patients after prior anthracycline, taxane and
capecitabine: phase 2 study results (Abstract 562). J Clin Oncol. 2005 Jun; 23(16S
part 1):19S.
228.
Perez EA, Hillman DW, Fishkin PA, Krook JE, Tan WW, Kuriakose PA,
Alberts SR, Dakhil SR. Phase II trial of dolastatin-10 in patients with advanced
breast cancer. Invest New Drugs. 2005 Jun; 23(3):257-61.
229.
Wasan KM, Goss PE, Pritchard PH, Shepherd L, Palmer MJ, Liu S, Tu D,
Ingle JN, Heath M, Deangelis D, Perez EA. The influence of letrozole on serum
lipid concentrations in postmenopausal women with primary breast cancer who have
completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). Ann Oncol. 2005
May; 16(5):707-15. Epub 2005 Apr 07.
230.
Lafky JM, Baron AT, Cora EM, Hillman DW, Suman VJ, Perez EA, Ingle
JN, Maihle NJ. Serum soluble epidermal growth factor receptor concentrations
decrease in postmenopausal metastatic breast cancer patients treated with letrozole.
Cancer Res. 2005 Apr 15; 65(8):3059-62.
231.
Burch PA, Mailliard JA, Hillman DW, Perez EA, Krook JE, Rowland KM,
Veeder MH, Cannon MW, Ingle JN. Phase II study of gemcitabine plus cisplatin in
patients with metastatic breast cancer-a North Central Cancer Treatment Group trial.
Am J Clin Oncol: Cancer Clin Trials. 2005 Apr; 28(2):195-200.
232.
Hobday TJ, Perez EA. Molecularly targeted therapies for breast cancer.
Cancer Control. 2005 Apr; 12(2):73-81.
233.
Muss HB, Von Roenn J, Damon LE, Deangelis LM, Flaherty LE, Harari PM,
Kelly K, Kosty MP, Loscalzo MJ, Mennel R, Mitchell BS, Mortimer JE, Muggia
F, Perez EA, Pisters PWT, Saltz L, Schapira L, Sparano J. ACCO: ASCO core
curriculum outline. J Clin Oncol. 2005 Mar 20; 23(9):2049-77.
234.
Perez EA, Suman VJ, Fitch TR, Mailliard JA, Ingle JN, Cole JT, Veeder
MH, Flynn PJ, Walsh DJ, Addo FK. A phase II trial of docetaxel and carboplatin as
first-line chemotherapy for metastatic breast cancer: NCCTG study N9932.
Oncology. 2005; 69(2):117-21. Epub 2005 Aug 23.
235.
Perez EA. Maximizing patient outcomes and optimizing anthracycline use
(Abstract 95). Cancer Invest. 2005; 23(Suppl 1):113-4.
236.
Miller KD, Wang M, Gralow J, Dickler M, Cobleigh MA, Perez EA,
Shenkier TN, Davidson NE. A randomized phase III trial of paclitaxel versus
paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic
breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group
(E2100) (Abstract 3). Breast Cancer Res Treat. 2005; 94(Suppl 1):S6. Abstract no.
3.
237.
Hudis C, Citron M, Berry D, Cirrincione C, Gradishar W, Davidson N,
Martino S, Livingston R, Ingle J, Perez E, Abrams J, Schilsky R, Ellis M, Muss H,
Norton L, Winer E. Five year follow-up on INT C9741: dose-dense (DD)
chemotherapy (CRx) is safe and effective (Abstract 41). Breast Cancer. 2005;
94(Suppl 1):S20-1.
238.
Wirk B, Geiger X, Hillman D, Perez EA. Concordance of HER2 and
hormone receptor expression in primary and recurrent breast cancer (Abstract 2019).
Breast Cancer Res Treat. 2005; 94(Suppl 1):S89.
239.
Perez EA, Suman VJ, Davidson NE, Kaufman PA, Martino S, Dakhil SR,
Ingle JN, Gersh BJ, Jaffe AS. Exploratory analysis from NCCTG N9831: do clinical
and laboratory characteristics predict cardiac toxicity of trastuzumab when
administered as a component of adjuvant therapy? (Abstract 2038). Breast Cancer
Res Treat. 2005; 94(Suppl 1):S96-7.
240.
Goetz MP, Suman VJ, Ingle JN, Nibbe AM, Visscher DW, Reynolds C,
Lingle WL, Erlander MG, Ma XJ, Sgroi DC, Perez EA, Couch FJ. A two-gene
expression ratio of HOXB13 and IL-17BR for prediction of recurrence and survival
in women receiving adjuvant tamoxifen (Abstract 312). Breast Cancer Res Treat.
2005; 94(Suppl 1):S34.
241.
Perez EA, Pusztai L, Van de Vijver M. Improving patient care through
molecular diagnostics. Semin Oncol. 2004 Oct; 31(5 Suppl 10):14-20.
242.
Baselga J, Gianni L, Geyer C, Perez EA, Riva A, Jackisch C. Future options
with trastuzumab for primary systemic and adjuvant therapy. Semin Oncol. 2004
Oct; 31(5 Suppl 10):51-7.
243.
Tack DK, Palmieri FM, Perez EA. Anthracycline vs nonanthracycline
adjuvant therapy for breast cancer. Oncology (Williston Park). 2004 Oct;
18(11):1367-76; discussion 1378, 1381.
244.
Perez EA, Suman VJ, Davidson NE, Kaufman PA, Martino S, Dakhil SR,
Ingle JN, Rodeheffer RJ, Gersh BJ, Jaffe AS. Effect of doxorubicin plus
cyclophosphamide on left ventricular ejection fraction in patients with breast cancer
in the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J
Clin Oncol. 2004 Sep 15; 22(18):3700-4.
245.
Perez EA, Suman VJ, Davidson NE, Martino S, Kaufman PA, Lingle WL,
Flynn PJ, Ingle JN, Visscher D, Jenkins RB. HER2 testing by local, central, and
reference laboratories in the NCCTG N9831 intergroup adjuvant trial (Abstract
567). Program/Proceedings of the American Society of Clinical Oncology. 2004 Jul
15; 22(14S):19S.
246.
Miller DV, Jenkins RB, Lingle WL, Davidson NE, Kaufman PA, Martino S,
Dakhil SR, Perez EA. Focal HER2/neu amplified clones partially account for
discordance between immunohistochemistry and fluorescence in-situ hybridization
results: data from NCCTG N9831 intergroup adjuvant trial (Abstract 568).
Program/Proceedings of the American Society of Clinical Oncology. 2004 Jul 15;
22(14S):19S.
247.
Ma CX, Steen P, Rowland KM, Niedringhaus RD, Kugler JW, Ingle
JN, Perez EA, Adjei AA. A phase II study of a combination of pemetrexed (PEM)
and gemcitabine (GEM) in patients with metastatic breast cancer (MBC): an
NCCTG study (Abstract 639). Program/Proceedings of the American Society of
Clinical Oncology. 2004 Jul 15; 22(14S):36S.
248.
Perez EA, Hillman DW, Mailliard JA, Ingle JN, Ryan JM, Fitch TR,
Rowland KM, Kardinal CG, Krook JE, Kugler JW, Dakhil SR. Randomized phase II
study of two irinotecan schedules for patients with metastatic breast cancer
refractory to an anthracycline, a taxane, or both. Program/Proceedings of the
American Society of Clinical Oncology. 2004 Jul 15; 22(14):2849-55.
249.
Miller DV, Leontovich AA, Lingle WL, Suman VJ, Mertens ML, Lillie J,
Ingalls KA, Perez EA, Ingle JN, Couch FJ, Visscher DW. Utilizing Nottingham
prognostic index in microarray gene expression profiling of breast carcinomas. Mod
Pathol. 2004 Jul; 17(7):756-64.
250.
Perez EA. Cardiac issues related to trastuzumab. Breast. 2004 Jun;
13(3):171-2.
251.
Mincey BA, Perez EA. Advances in screening, diagnosis, and treatment of
breast cancer. Mayo Clin Proc. 2004 Jun; 79(6):810-6.
252.
Perez EA, Geoffroy FJ, Hillman S, Johnson EA, Farr GH Jr, Tazelarr HD,
Hatfield AK, Krook JE, Maillard JA, Levitt R, Marks RS. Phase II study of oral
etoposide and intravenous paclitaxel in extensive-stage small cell lung cancer. Lung
Cancer. 2004 Jun; 44(3):347-53.
253.
Perez EA, Rodeheffer R. Clinical cardiac tolerability of trastuzumab. J Clin
Oncol. 2004 Jan 15; 22(2):322-9.
254.
Perez EA. Gemcitabine and platinum combinations in patients with breast
cancer previously treated with anthracyclines and/or taxanes. Clin Breast Cancer.
2004 Jan; 4 Suppl 3:S113-6.
255.
Perez EA. Carboplatin in combination therapy for metastatic breast cancer.
Oncologist. 2004; 9(5):518-27.
256.
Perez EA. Management recommendations for adjuvant systemic breast
cancer therapy. Breast Dis. 2004; 21:15-21.
257.
Grant CS, Hartmann LC, Suman VJ, Dumesic DA, Ingle JN, Wickerham
DL, Gelber RD, Perez EA. Menstrual cycle and surgical treatment of breast cancer:
findings from the NCCTG N9431 study (Abstract 5088). Breast Cancer Res Treat.
2004; 88(Suppl 1):S213.
258.
Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW,
Flockhart DA, Adjei AA, Weinshilboum RM, Couch FJ, Lingle W, Desta Z, Perez
EA, Ingle JN. Pharmacogenomic determinants of outcome with tamoxifen therapy:
findings from the randomized North Central Cancer Treatment Group adjuvant
breast cancer trial 89-30-52 Breast Cancer Res Treat. 2004; 88(Suppl 1):S35.
Abstract no. 314.
259.
Ingle JN, Rowland KM, Suman VJ, Mirchandani D, Bernath AM,
Camoriano JK, Perez EA. Evaluation of fulvestrant in women with advanced breast
cancer and progression on prior aromatase inhibitor therapy: a phase II trial of the
North Central Cancer Treatment Group (Abstract 409). Breast Cancer Res Treat.
2004; 88(Suppl 1):S38.
260.
Tan WW, McDonough MD, Mincey BA, Perez EA. Fluorodeoxyglucose
positron emission tomography as a decision making tool for detection of recurrent or
metastatic breast cancer (Abstract 6007). Breast Cancer Res Treat. 2004; 88(Suppl
1):S222.
261.
Perez EA, Josse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP,
Shenkier TN, Tozer RG, Palmer MJ, Shepherd LE, Tu D, Goss PE. Effect of
letrozole versus placebo on bone mineral density in women completing >= 5 years
(yrs) of adjuvant tamoxifen: ncic ctg ma.17b. Breast Cancer Res Treat. 2004;
88(Suppl 1):S36.
262.
Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione
M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton
L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL. A randomized trial of
letrozole in postmenopausal women after five years of tamoxifen therapy for earlystage breast cancer. N Engl J Med. 2003 Nov 6; 349(19):1793-802. Epub 2003 Oct
09.
263.
Palmieri FM, Perez EA. Recent advances in adjuvant therapy for breast
cancer. Semin Oncol Nurs. 2003 Nov; 19(4 Suppl 2):10-6.
264.
Jatoi A, Stella PJ, Hillman S, Mailliard JA, Vanone S, Perez EA, Cannon
MW, Geyer S, Wiesenfeld M, Jett JR. Weekly carboplatin and paclitaxel in elderly
non-small-cell lung cancer patients (>or=65 years of age): a phase II North Central
Cancer Treatment Group study. Am J Clin Oncol. 2003 Oct; 26(5):441-7.
265.
Sargent D, Hillman S, An MW, Kugler J, Goldberg R, Perez E, Jett J,
Buckner J. A critical evaluation of tumor response in solid tumor cancer clinical
trials Control Clin Trials. 2003 Jun; 24(3S):172S. Abstract no. P152.
266.
Perez EA, Jenkins RB. Correspondence - Re: HER2 testing in the real world
- Response. J Natl Cancer Inst. 2003 Apr 16; 95(8):628-9.
267.
Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ,
Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, Carpenter J, Hurd D,
Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB,
Norton L. Randomized trial of dose-dense versus conventionally scheduled and
sequential versus concurrent combination chemotherapy as postoperative adjuvant
treatment of node-positive primary breast cancer: first report of Intergroup Trial
C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003 Apr 15;
21(8):1431-9. Epub 2003 Feb 13.
268.
Formenti SC, Volm M, Skinner KA, Spicer D, Cohen D, Perez E, Bettini
AC, Groshen S, Gee C, Florentine B, Press M, Danenberg P, Muggia F.
Preoperative twice-weekly paclitaxel with concurrent radiation therapy followed by
surgery and postoperative doxorubicin-based chemotherapy in locally advanced
breast cancer: a phase I/II trial. J Clin Oncol. 2003 Mar 1; 21(5):864-70.
269.
Perez E. Adjuvant chemotherapy: controversies and the role of taxanes.
Breast J. 2003 Jan-Feb; 9 Suppl 1:S25-8.
270.
Perez EA. Adjuvant therapy approaches to breast cancer: should taxanes be
incorporated? Curr Oncol Rep. 2003 Jan; 5(1):66-71.
271.
Perez EA, Rowland KM, Suman VJ, Ingle JN, Salim M, Loprinzi CL, Flynn
PJ, Mailliard JA, Kardinal CG, Krook JE, Wiesenfeld M. N98-32-52: efficacy and
tolerability of two schedules of paclitaxel, carboplatin and trastuzumab in women
with HER2 positive metastatic breast cancer: a North Central Cancer Treatment
Group randomized phase II trial. Breast Cancer Res Treat 2003; 82(Suppl 1):S47.
272.
Perez EA, Gandara DR, Edelman MJ, O'Donnell R, Lauder IJ, DeGregorio
M. Phase I trial of high-dose tamoxifen in combination with cisplatin in patients
with lung cancer and other advanced malignancies. Cancer Invest. 2003; 21(1):1-6.
273.
Perez EA, Lambert-Falls R, Deutsch M, Desch C, Justice G, Cosgriff T,
Headly D, Palmieri FM. Phase III adjuvant trial of concurrent epirubicin/taxane vs.
sequential epirubicin/cyclophosphamide followed by taxane for node positive breast
cancer: safety analysis. Breast Cancer Res Treat. 2002 Dec; 76(Suppl 1):S158.
274.
Perez EA. Nail toxicity related to weekly taxanes: an important issue
requiring a change in common toxicity criteria grading? In reply. J Clin Oncol. 2002
Nov 1; 20(21):4405.
275.
Loprinzi L, Barton DL, Sloan JA, Zahasky KM, Smith DA, Pruthi S,
Novotny PJ, Perez EA, Christensen BJ. Pilot evaluation of gabapentin for treating
hot flashes. Mayo Clin Proc. 2002 Nov; 77(11):1159-63.
276.
Perez EA, Geeraerts L, Suman VJ, Adjei AA, Baron AT, Hatfield AK,
Maihle N, Michalak JC, Kuross SA, Kugler JW, Lafky JM, Ingle JN. A randomized
phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients
with metastatic breast cancer. Ann Oncol. 2002 Aug; 13(8):1225-35.
277.
Roche PC, Suman VJ, Jenkins RB, Davidson NE, Martino S, Kaufman PA,
Addo FK, Murphy B, Ingle JN, Perez EA. Concordance between local and central
laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst.
2002 Jun 5; 94(11):855-7.
278.
Qu GZ, Perez EA. Gemcitabine and targeted therapy in metastatic breast
cancer. Semin Oncol. 2002 Jun; 29(3 Suppl 11):44-52.
279.
Perez EA, Vogel CL, Irwin DH, Kirshner JJ, Patel R. Weekly paclitaxel in
women age 65 and above with metastatic breast cancer. Breast Cancer Res Treat.
2002 May; 73(1):85-8.
280.
Loprinzi CL, Sloan JA, Perez EA, Quella SK, Stella PJ, Mailliard JA,
Halyard MY, Pruthi S, Novotny PJ, Rummans TA. Phase III evaluation of
fluoxetine for treatment of hot flashes. J Clin Oncol. 2002 Mar 15; 20(6):1578-83.
281.
Lafky JM, Baron AT, Greenwood TM, Wahner-Roedler DL, Johnson RE,
Buenafe MC, Trippel SJ, Rhodes DJ, Perez EA, Mincey BA, Maihle NJ.
Associations between gonadotropins or steroid hormones and soluble EGFR/ErbB1
(sErbB1), but not sErB2, may predict breast disease. (Abstract 1180). Proc Am
Assoc Cancer Res. 2002 Mar; 43:236.
282.
Perez EA, Roche PC, Jenkins RB, Reynolds CA, Halling KC, Ingle JN,
Wold LE. HER2 testing in patients with breast cancer: poor correlation between
weak positivity by immunohistochemistry and gene amplification by fluorescence in
situ hybridization. Mayo Clin Proc. 2002 Feb; 77(2):148-54.
283.
Mincey BA, Vallow LA, Perez EA. Adjuvant therapy trials of radiotherapy
and systemic treatment for breast cancer. Curr Oncol Rep. 2002 Jan; 4(1):1.
284.
Mincey BA, Palmieri FM, Perez EA. Adjuvant therapy for breast cancer:
recommendations for management based on consensus review and recent clinical
trials. Oncologist. 2002; 7(3):246-50.
285.
Kuriakose P, Gandara DR, Perez EA. Phase I trial of edatrexate in advanced
breast and other cancers. Cancer Invest. 2002; 20(4):473-9.
286.
Maihle NJ, Lafky JM, Baron AT, Boardman CH, Greenwood TM,
Christensen TA, Reiter JL, Cora EM, Lee H, Suman VJ, Fishman DA, Perez EA,
Podratz KC. EGF receptor/ErbB isoforms as serum biomarkers in breast and ovarian
cancer. Journal of Clinical Ligand Assay. 2002 Spr; 25(1):57-60.
287.
Perez EA, Russell CA. Metastatic breast cancer. In: In: Jatoi I, editor..
Manual of Breast Diseases. Philadelphia: Lippincott Williams & Willkins; 2002. p.
365-87.
288.
Perez EA. Anti-cancer treatment-12th international congress: Feb 4-7 2002,
Paris, France. Idrugs. 2002; 5(3):222-3.
289.
Perez EA, Hillman DW, Mailliard JA, Ingle JN, Ryan JM, Fitch TR,
Rowland KM, Kardinal CG, Krook JE, Kugler JW, Dakhil SR. Randomized phase II
study of 2 schedules of irinotecan (CPT-11) for patients (pts) with refractory
metastatic breast cancer (MBC): an NCCTG cooperative group study Proc Am Soc
Clin Oncol. 2002; 21(1):52a. Abstract no. 206.
290.
Schwartzberg L, Irwin D, Havlin K, Levine M, Perez E, Albain KS. Phase II
study of a novel, fixed-dose schedule of UFT plus leucovorin (UFT/L) for patients
(pts) with progressive, metastatic breast cancer after prior chemotherapy (Abstract
240). Program/Proc Am Soc Clin Oncol. 2002; 21(1):61A.
291.
Loprinzi CL, Barton DL, Sloan JA, Zahasky KM, Smith D, Pruthi S,
Novotny PJ, Perez EA. Pilot evaluation of gabapentin for alleviation of hot flashes
Program/Proc Am Soc Clin Oncol. 2002; 21(1):362a. Abstract no. 1444.
292.
Mailliard JA, Jatoi A, Hillman S, Stella PJ, Vanone S, Perez EA, Cannon
MW, Geyer S, Wiesenfeld M, Jett JR. Weekly carboplatin and paclitaxel in elderly
non-small cell lung cancer patients (greater than or equal to 65 years of age): a phase
II North Central Cancer Treatment Group study Proc Am Soc Clin Oncol. 2002;
21(1):383a. Abstract no. 1530.
293.
Perez EA, Vogel CL, Irwin DH, Kirshner JJ, Patel R. Multicenter phase II
trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol.
2001 Nov 15; 19(22):4216-23.
294.
Perez EA. The role of adjuvant monoclonal antibody therapy for breast
cancer: rationale and new studies. Curr Oncol Rep. 2001 Nov; 3(6):516-22.
295.
Baron AT, Lafky JM, Suman VJ, Hillman DW, Buenafe MC, Boardman CH,
Podratz KC, Perez EA, Maihle NJ. A preliminary study of serum concentrations of
soluble epidermal growth factor receptor (sErbB1), gonadotropins, and steroid
hormones in healthy men and women. Cancer Epidemiol Biomarkers Prev. 2001
Nov; 10(11):1175-85.
296.
Hortobagyi GN, Perez EA. Integration of trastuzumab into adjuvant
systemic therapy of breast cancer: ongoing and planned clinical trials. Semin Oncol.
2001 Oct; 28(5 Suppl 16):41-6.
297.
Reinholz MM, Iturria SJ, Perez EA, Ingle JN, Roche PC. Differential gene
expression of selective TGF-beta family members and osteopontin in breast tumor
tissue: analysis by real-time quantitative PCR. Breast Cancer Res Treat 2001 Oct;
69(3):296.
298.
Roche PC, Mertens ML, Couch FJ, Ingle JN, Leontovich AA, Perez EA,
Lillie J. Utilization of gene expression profiling to identify markers of disease
recurrence in node-negative breast cancer. Breast Cancer Research & Treatment.
2001 Oct; 69(3):213.
299.
Perez EA. Adjuvant anti-HER2 monoclonal antibody therapy - ready for
breast cancer? Breast. 2001 Aug; 10(Suppl 3):161-163.
300.
Valero V, Perez E, Dieras V. Doxorubicin and taxane combination regimens
for metastatic breast cancer: focus on cardiac effects. Semin Oncol. 2001 Aug; 28(4
Suppl 12):15-23.
301.
Perez EA. Metastatic bone disease in breast cancer: the patient's perspective.
Semin Oncol. 2001 Aug; 28(4 Suppl 11):60-3.
302.
Mincey BA, Bammer T, Atkinson EJ, Perez EA. Role of axillary node
dissection in patients with T1a and T1b breast cancer: Mayo Clinic experience. Arch
Surg. 2001 Jul; 136(7):779-82.
303.
Lara PN Jr, Gandara DR, Longmate J, Gumerlock PH, Lau DH, Edelman
MJ, Gandour-Edwards R, Mack PC, Israel V, Raschko J, Frankel P, Perez EA, Lenz
HJ, Doroshow JH. Activity of high-dose toremifene plus cisplatin in platinumtreated non-small-cell lung cancer: a phase II California Cancer Consortium Trial.
Cancer Chemother Pharmacol. 2001 Jul; 48(1):22-8.
304.
Lafky JM, Baron AT, Suman VJ, Hillman DW, Buenafe MC, Boardman CH,
Podratz KC, Perez EA, Maihle NJ. Soluble epidermal growth factor receptor
(sErbB1), gonadotropin, and steroid hormone levels in healthy men and women:
Reference values of the p110 sErbB1 serum biomarker (Abstract 938). Am J
Epidemiol. 2001 Jun 1; 153(11 Suppl):S252.
305.
Perez EA, Romond E. Trastuzumab in adjuvant therapy for breast cancer.
Breast. 2001 Feb; 10(Suppl 1):S11.
306.
Perez EA. Doxorubicin and paclitaxel in the treatment of advanced breast
cancer: efficacy and cardiac considerations. Cancer Invest. 2001; 19(2):155-64.
307.
Loprinzi CL, Sloan JA, Perez EA, Quella SK, Stella PJ, Mailliard JA,
Halyard MY, Pruthi S, Novotny PJ, Rummans TA. Fluoxetine reduces hot flashes.
(Abstract 199). Program/Proc Am Soc Clin Oncol. 2001; 20(1 of 2):51A.
308.
Perez EA, Vogel CL, Irwin DH, Kirschner JJ, Patel R. Comparative efficacy
and toxicity of weekly paclitaxel in women age greater than or equal to 65 and age <
65 with metastatic breast cancer (MBC). (Abstract 166). Program/Proc Am Soc Clin
Oncol. 2001; 20(1 of 2):42A.